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ABSTRACT
There is increasing interest in the medical and behavioral health communi-
ties towards developing effective strategies for the treatment of chronic diseases.
Among these lie adaptive interventions, which consider adjusting treatment dosages
over time based on participant response. Control engineering offers a broad-based
solution framework for optimizing the effectiveness of such interventions. In this
thesis, an approach is proposed to develop dynamical models and subsequently, hy-
brid model predictive control schemes for assigning optimal dosages of naltrexone,
an opioid antagonist, as treatment for a chronic pain condition known as fibromyal-
gia.
System identification techniques are employed to model the dynamics from the
daily diary reports completed by participants of a blind naltrexone intervention trial.
These self-reports include assessments of outcomes of interest (e.g., general pain
symptoms, sleep quality) and additional external variables (disturbances) that affect
these outcomes (e.g., stress, anxiety, and mood). Using prediction-error methods, a
multi-input model describing the effect of drug, placebo and other disturbances on
outcomes of interest is developed. This discrete time model is approximated by a
continuous second order model with zero, which was found to be adequate to cap-
ture the dynamics of this intervention. Data from 40 participants in two clinical tri-
als were analyzed and participants were classified as responders and non-responders
based on the models obtained from system identification.
The dynamical models can be used by a model predictive controller for auto-
mated dosage selection of naltrexone using feedback/feedforward control actions
in the presence of external disturbances. The clinical requirement for categorical
(i.e., discrete-valued) drug dosage levels creates a need for hybrid model predictive
control (HMPC). The controller features a multiple degree-of-freedom formulation
that enables the user to adjust the speed of setpoint tracking, measured disturbance
i
rejection and unmeasured disturbance rejection independently in the closed loop
system. The nominal and robust performance of the proposed control scheme is
examined via simulation using system identification models from a representative
participant in the naltrexone intervention trial. The controller evaluation described
in this thesis gives credibility to the promise and applicability of control engineering
principles for optimizing adaptive interventions.
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Chapter 1
INTRODUCTION
1.1 Motivation
Chronic and relapsing diseases such as diabetes, hypertension, mental disorders,
substance abuse, HIV/AIDS and cancer are among the leading causes of human
suffering and mortality worldwide, with the health care costs running in trillions of
dollars [1]. Traditional medical practice is based on treatment plans designed for a
typical or an average response where drug dosages are assigned without considering
an individual’s dynamics and optimal dosage criteria. Many of these dosage strate-
gies are inspired from the acute care model and in spite of effective drugs, are not
necessarily efficient for long lasting or chronic disorders. There has been increased
interest in efficient strategies to treat chronic diseases, and in particular for more
personalized medicine by taking into account the characteristics of the individual
and their response to the treatment in presence of external disturbances [2, 3]. A
control system paradigm, using models describing the dynamics and predictive con-
trol to assign drug dosages, is expected to result in more efficient treatment plans
which will minimize waste and maximize effectiveness of the treatment.
The use of adaptive dosage strategies, where adapting dosages is based on par-
ticipant response over time, is the key motivation for use of control systems. Con-
cepts from control theory can be used as tools for transforming the state of a system
to a desired condition; these can be applied, under certain conditions, to any phe-
nomena described as a dynamical system. Traditionally, typical applications have
been in areas where the physics of the system is either completely or partially under-
stood (e.g., by using principles such as conservation of energy) and/or the system
is inanimate like in industrial and process systems, aerospace, robotics, power sys-
tems and electronics. Considerable interest has been seen in past few decades for
application of control in unconventional areas like biology and medicine [2, 4, 3],
social and behavioral science [5, 6, 7] and supply chains and economics [8, 9]. In
this thesis, we address the application of control engineering principles for optimiz-
ing a treatment used for chronic pain disorder known as fibromyalgia [10, 11, 12].
We approach this problem from a systems and controls point-of-view where the
systems thinking is used to improve disorder diagnosis and its treatment. First, we
build models using secondary data analysis on information collected from clinical
trials to understand the dynamics of a drug, known as naltrexone, on fibromyal-
gia symptoms; then, we use predictive control techniques to find the best optimal
dosage plan and demonstrate, using simulation on estimated models, that the re-
quired performance can be achieved under model error and in the presence of con-
straints.
1.2 Fibromyalgia - an Introduction
Fibromyalgia Syndrome (also referred to as FM or FMS) is a medical disorder
characterized by chronic widespread pain. The characteristic symptoms of FM
are diffuse musculoskeletal pain and sensitivity to mechanical stimulation at soft
tissue tender points [13, 14]. Other primary symptoms of FM include fatigue, sleep
disturbance, joint stiffness, bowel and bladder abnormalities, numbness, tingling,
and cognitive or mood dysfunction. It is largely believed that various behavioral
and psychological factors such as stress and anxiety are associated with symptoms
of FM [15], however they are unlikely the cause. The core symptom of FM is made
up of overall daily pain and fatigue although most of the sufferers also complain of
poor sleep quality. It is also important to note that not all individuals suffering from
FM experience all associated symptoms.
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While no specific laboratory test can confirm FM, most patients present with
a history of widespread pain and fatigue conditions. Another important issue with
FM is that its etiology is largely unknown and without any scientific consensus
[16]. FM is a form of chronic disorder that can be more easily grouped with dis-
orders due to break down of the physiology of the body, as a consequence of any
number of reasons. Diabetes, epilepsy, hypertension, FM are very distinct from
other disorders such as those caused by infections like HIV/AIDS or tuberculosis;
these infectious diseases follow a mechanism which can be traced back and repre-
sented mathematically with relative ease as compared to complex chronic disorders
resulting from physiological problems.
As the cause(s) for FM are unknown, uncertain or disputed and due to its chronic
nature, it has been difficult to single out a specific type of treatment for this disease.
There is a good evidence to suggest that naltrexone, an opioid antagonist, has a
strong neuroprotective role [10, 17] and may be a potentially effective drug for
a disease like FM which has a clear neuromuscular origin. A low dose naltrex-
one (LDN) intervention was conducted by Dr. Jarred Younger and colleagues at
the Stanford Systems Neuroscience and Pain Lab (SNAPL), Stanford University
School of Medicine. In this thesis, experimental data from these clinical trials con-
ducted on a sample population (Npar = 40) is evaluated for a control engineering
based optimized intervention.
1.3 Adaptive Interventions and Personalized Medicine
With recent understanding and advancements in genetics (like the human genome
project), metabolism and pharmacology, there has been increasing interest in the
medical community toward developing improved strategies for treating disease by
relying on personalized medicine [18]. Similarly in the behavioral sciences, adap-
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tive interventions is the umbrella term used to describe the use of individualized
optimal strategies used for prevention, treatment and management of chronic and
relapsing disorders [19].
Increased information about the individual, such as the dynamical response
over time to a particular drug, is key to the success of adaptive interventions. Af-
ter a good modeling base, an effective treatment strategy has to be implemented
which can maintain the desired response in time and space, under disturbances.
Individually-tailored strategies can increase intervention potency and greater effi-
ciency can be expected than approaches which apply same strategy to a large co-
hort [5]. In line with this requirement, the primary characteristic of an adaptive
intervention is the focus on individualized treatment, which can vary based on the
measured response, and is compatible with the aim of a control system. In this
work, we use control engineering as an framework for implementing adaptive in-
terventions.
Within the last ten years, more and more efforts are being placed by commu-
nities from control engineering, biology, medicine and psychology, through inter-
disciplinary collaboration, towards development and use of systems, optimization
and control theory for better understanding of biological systems in general, and in
particular for diagnosis and treatment of diseases [3, 20, 21, 22]. Among the most
successful approach for systems medicine has been in HIV management [21, 23]
with significant developments in insulin control [24, 25], anesthesia delivery [26],
epilepsy management [27], depression management [28] and in the behavioral sci-
ences [5, 6, 19]. It is interesting to note that in the areas where a better dynamical
model is available (e.g., infectious diseases), control strategies have had greater
success. Dynamical modeling is either done through first principles [23] or with a
combination with various parameter estimation methods on different layers of ab-
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straction e.g., In system biology, most of the effort has been on understanding of
the dynamics on cellular level [29] where as a systems medicine approach can focus
on an overall pharmacodynamic response [30]. Finally, the drug dosage methods
have been implemented using various optimal control schemes [21, 23]. Model
Predictive Control (MPC) is particularly suited for designing treatment regimens
with its finite horizon receding control policy where the typical treatment related
constraints can also be well integrated in the design [31, 32].
1.4 Optimized Interventions: A Control Engineering Approach
During a typical treatment phase, clinicians gauge the response of a patient by not-
ing changes in symptoms or expected outcomes and suggest changes in dosages (if
required). Even at the disposal of extensive medical history, the approach to assign
drug dosages is based more or less on the intuition of the physician; on how they
asses changes in symptoms and how they expect these to change with alterations in
dosage. Clearly, this approach may not result in an effective intervention. Instead
by making use of systematic operationalized techniques as used in control engi-
neering to model and control the dynamics of the disorder, we can achieve better
results. This will result in maximizing the possible benefits from the drug from ex-
isting resources. It should be noted that the term ‘adaptive’ as is used in this thesis
is typically used in behavioral science and psychology literature [33] to imply that
the dosage plans are designed with keeping the dynamics of the process in mind and
should not be confused with adaptive as used in control literature [34]. Of course,
‘adaptive control’ (where the dynamical model and corresponding control law is
updated during control actions) can be also be implemented but that avenue has not
been pursued in this thesis.
The engineering approach to designing optimized interventions evaluated in this
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thesis can be analyzed in two areas: a) dynamic modeling using system identifica-
tion and b) control system design using hybrid model predictive control . They are
discussed in brief below and, in detail, in the following chapters.
1.4.1 Dynamical Modeling
Understanding of the dynamics of a complex system is a fundamental prerequi-
site for successful control engineering implementation. For a complex phenomena,
the approach of describing system behavior as function of its internal components
(whose dynamics are then assumed to be known) is difficult as well as may be self
defeating in case of chronic disorders, for example, where the dynamics are due to
complex interaction between components which may be unexplained at the elemen-
tal level. It can be argued that a ‘systems level’ thinking is best suited to explain
these complex dynamics. Systems approach can be understood as a more holistic
way of analysis where a system can be analyzed as a single functional unit without
breaking down into smaller components, a reductionist approach, or without full
understanding of the internal mechanisms. This concept is largely suited for and so
has been adopted in systems biology [3, 20, 29].
The classical modeling approach relies on the use of first principles i.e. the
dynamics describing the exact mechanisms or physics of the internal components
of the system. In light of unknown dynamics of FM, we evaluate a system identi-
fication approach for building linear time-invariant models. System identification
is a method, with its root in statistics, which uses experimental input-output data
to infer a dynamical model [35, 36]. In this thesis, we perform a secondary data
analysis on daily reports completed by intervention participants from a previously
conducted clinical trial. Inferring model using data is also of particular interest in
this work as underlying causes of FM remain largely unknown and hence a largely
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reductionist approach to this problem is rather difficult.
In pharmacological interventions, it is important that the drug dynamics are well
understood. It is not enough to just note whether a particular drug produces changes
(as is typically noted in the medical literature) but also the speed and magnitude of
these effects. Typically for testing new drugs/treatment methods, clinical trials are
conducted. For scientific accuracy and to prevent personal bias, clinical trails are
conducted as a blind study with some sort of experimental control. In a typical
clinical trial, number of endpoints are available which can be potentially grouped
together as inputs and outputs to estimate a causal relationship. In the clinical trial
conducted by Younger et al., the information is available as ‘daily diary reports’.
These diary reports include daily self-assessments of outcomes of interest (e.g., pain
severity, sleep quality) and other external variables that may affect these outcomes
(such as stress, gastric symptoms etc) in addition to drug and placebo. Figure 1.1a
shows time series of variables FM sym or pain severity and sleep quality (on a
scale of 0-100) associated with the clinical trial for one participant. It can be noted
that, for this participant, the pain magnitude goes down with introduction of drug
suggesting a strong response to medication. The drug (naltrexone) concentration
used in this study was 4.5 mg. Placebo is measured as a unit dosage. In Figure 1.1b,
time series for three variables (anxiety, stress and mood) are shown which act as
disturbances.
The focus of our modeling research has been on identifying parsimonious mod-
els that capture inherent dynamics of drug intervention for FM. We use prediction-
error methods to estimate a discrete time model from experimental data and then
a simplification to a second order continuous model structure with zero. It is im-
portant to note that we are not modeling the internal mechanisms of FM but rather
how the drug and external factors affect a number of FM symptoms so that the
7
0 10 20 30 40 50 60 70 80
0
50
100
R
es
po
ns
e
Daily Diary Variables
 
 
0 10 20 30 40 50 60 70 80
0
50
100
R
es
po
ns
e
 
 
Overall Sleep
FM Symptoms
0 10 20 30 40 50 60 70 80
0
5
St
re
ng
th
 (m
g)
 
 
0
0.5
1
Time (days)
Pl
ac
eb
o
Drug
Placebo
(a)
0 10 20 30 40 50 60 70 80
0
50
100
R
es
po
ns
e
 
 
0 10 20 30 40 50 60 70 80
0
20
40
R
es
po
ns
e
 
 
0 10 20 30 40 50 60 70 80
60
80
100
Time (Days)
R
es
po
ns
e
 
 
Stress
Anxiety
Mood
(b)
Figure 1.1: Selected variables associated with naltrexone intervention of fibromyal-
gia, as shown for a representative participant.
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predictive information can be used by a controller to assign dosages based on mea-
sured participant responses. Linear models will be an approximation of what may
be a nonlinear phenomena but with well developed techniques for linear modeling
and control, it is possible to achieve desired performance in the intervention. It
is worth noting that contrary to typical applications of system identification, this
work is a secondary analysis of data and does not involve any “input signal” or an
experimental design. It is characteristic of clinical trials to follow a fixed protocol
for assigning drug dosage and hence in this scenario, we are typically left with no
option of an experimental design for influencing system excitation as is possible
in typical engineering problems [35]. Likewise, the nature of the protocol creates
issues with using the data for meaningful cross validation.
1.4.2 Control System Design
In a control engineering approach to adaptive interventions, the controller assigns
dosages to each participant as dictated by model dynamics, problem constraints,
and in the presence of measured and unmeasured disturbances. We use control
algorithms to decide on the dosage level required for a particular participant based
on the dynamics of the disorder as well as the magnitude of relief expected under
given constraints. Simple techniques typically used in adaptive interventions, like
IF-THEN rules, will not yield good performance for a lagged response [5]. Instead,
we can rely on a well designed control system to assign dosages based on model
dynamics and performance requirements of the intervention.
We describe a classical feedback/feedforward control system as shown in Fig-
ure 1.2. Here, P represents the plant or dynamics expected of the drug intervention
on outcomes, Pd represents the disturbance plant modeling the effect of external
variables on outcomes, C is the controller which assigns the dosages as per changes
9
in symptoms in feedback configuration. C′ is the feedforward controller which is
used to compensate for measured disturbances dm. The input to the controller is the
error function e (generated due to feedback mechanism) which is an indicator of
the difference between the measured [y] and desired [r] controlled variable(s).
r −
e
y
 C 
u  + 
diuF

+

+
n
P  
yp+
dm
Pd

ffC′
 
dum
+
ff

Figure 1.2: A classical feedback/feedforward control system.
The variables dm and dum represent the measured and unmeasured disturbances
acting on the system; dm is the disturbance acting through known dynamics (Pd)
or measured disturbance; and dum is the output disturbance which is more or less
beyond the control of the intervention process or unmeasured disturbances. di is
an unmeasured ‘input’ disturbance. In an adaptive intervention setting, the input
disturbance can be a clinical judgment in which a physician suggest a different
dosage than that assigned by the controller; it can also be an error in preparing
the compound at the pharmacy, or might be related to adherence of the patient to
the treatment. n is the measurement noise to model the imprecise measurement of
variables. This control setup can be designed for low frequency reference tracking
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and high frequency unmeasured disturbance rejection through the feedback loop
and measured disturbance rejection through the feedforward loop.
In this work, we use Model Predictive Control (MPC) as the algorithmic frame-
work for making these systematic dosage assignments. This control technology
effectively combines feedback-feedforward control action by on line optimization
of a cost function in a receding horizon [37]. It is also naturally suited for multi-
input multi-output (MIMO) systems with constraints. The feedforward type control
action of MPC is very useful for addressing disturbances which may be known a
priori and can be measured in the course of the intervention. Furthermore, the
controller can respond to unmeasured disturbances; for example, the intervention
participant may undergo some unusual or unpredictable event that will affect FM
symptoms, consequently requiring an adjustment to their current dosage.
The dynamical systems model serves as the basis for applying model predictive
control as a decision algorithm for dosage selection of naltrexone in the face of the
external disturbances. The categorical/discrete-event nature of the dosage assign-
ment creates a need for hybrid model predictive control (HMPC) schemes, which
we contrast with its continuous counterpart. A multiple degree-of-freedom formu-
lation [31] is evaluated that enables the user to adjust the speed of setpoint track-
ing, measured disturbance rejection and unmeasured disturbance rejection indepen-
dently in the closed loop system. In Chapter 4, simulation results for a represen-
tative participant in the presence of significant plant-model mismatch demonstrate
the performance and broad-based applicability of a predictive control approach to
these class of intervention problems.
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1.4.3 Example Case
Consider a case for an adaptive intervention. First, since this drug has not been
established as a standard drug for FM, the participant has to undergo an experiment
or a clinical trial. The aim is to judge the effectiveness of drug as well as to collect
data to build a model. For an adaptive intervention, as was discussed in section
1.4.1, we rely on estimating models using system identification methods. For cases
where the drug/treatment is standard for a given disorder, a clinical trial may still
be conducted to collect initial experimental data for modeling. Also, in these cases
the system identification methods can be combined with drug pharmacokinetics and
pharmacodynamics to build more accurate grey box models.
To take a specific example, let us consider drug dosage assignment to reduce FM
symptoms report (FM sym) by 9.5 points. The clinical constraint is that bounds for
drug dosages have to be between 0−13.5 mg. In addition to that, the drug or u(t)
can take only discrete values. We use a continuous second order identified model
describing the basic dynamics of the intervention as shown:
FMsym(s)
Drug(s)
= G1(s) =
−2.47(1.96s+1)
(1.57)2s2 +2(1.26)(1.57)s+1 (1.1)
and use the hybrid MPC technique [31] to assign dosages at daily intervals. The
output change is shown in Figure 1.3 and is compared with a ‘continuous’ MPC
where u(t) can take any real value in its domain. The pain report is assumed to
start from 50 at t = 0. The figure also describes the measured disturbance from
an anxiety report (11.02 points) acting at t = 25 day and unmeasured disturbance
(9.63 points) at t = 45 day. The tuning parameters related to the multi degree-of-
freedom formulation are (αr,αd, fa)= (0.5,0.5,0.5). It can be noted that the hybrid
MPC assigns dosages under given constraints where the controller performance
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is comparable to the case where dosages can be continuous. The details of the
controller development are included in Chapter 4.
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Figure 1.3: Performance of hybrid MPC as compared to continuous MPC for set-
point change, measured disturbance (anxiety) and unmeasured disturbance for par-
ticipant 5. Reference is shown by a dotted (red) line.
The controller evaluation can be expanded to include a plant model mismatch
where a real time system can measure the changes in symptoms and then can assign
dosage based on those mismatch errors. All this functionality can be incorporated
in a model predictive control framework while being tuned for robustness and per-
formance. With exceptional advances in computing technologies in past few years,
there is a large scope of using control engineering for implementing an adaptive
intervention and personalized medicine strategy.
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1.5 Contribution of the Thesis
In this thesis, we have tried to address various aspects of adaptive intervention to-
wards using system identification and model predictive control technique for as-
signing optimal treatment plans. Some of the aspects of model identification that
we touch upon are:
• Use of secondary analysis on clinical data to asses how do the participants
respond to drug over time and if so, then how strongly? We discuss how
various variables interact within the context of the participant to produce ob-
served effect and its effect on control strategies. Independent variables like
drug and placebo can be classified as exogenous manipulated variables in a
typical clinical trial. Other variables can be grouped as disturbances. Typical
outcomes of interest such as FM symptoms or sleep are chosen as outputs.
• Methods for parameter estimation and model validation. One of the fun-
damental challenges in working with secondary clinical trial data has been
working with finite data set with fixed protocol (no option of user choice
in signal designs). The fixed protocol also limits the ability to validate es-
timated model by cross validation without causing large errors in shortened
estimation data set. Prediction-error methods are used to estimate a linear
time-invariant (LTI) model.
• Identification of causal and feedback relationships from experimental data.
Without a priori knowledge, system identification from experimental data
generated from feedback loops can be difficult. The direct prediction-error
approach is used which can work well with closed loop data [35, 38].
• How does the protocol followed for the trial influence model quality?
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The estimated models are then used in a hybrid MPC framework to assign
dosages. The control scheme is chosen such that it address the nominal and ro-
bust performance requirements. Some of the control aspects covered are:
• How can an adaptive strategy, which can incorporate all the clinical con-
straints, be implemented? The aim of the control problem is to assign optimal
dosages and its effectiveness, in real life setting, will be based on predictive
quality of estimated models.
• How is nominal performance evaluated for this control scheme? How do
various disturbances effect the control performance?
• How robust is the identification-control paradigm used? This scenario is
shown as proof-of-concept by simulating model perturbations and the result-
ing control action was noted to be satisfying in presence of model errors. The
proper trade-off between modeling effort and controller performance will de-
pend on clinical requirements.
Although this work has been developed for the naltrexone intervention for FM,
the general framework for system identification can be extrapolated to any similar
drug clinical trial and the used control scheme is effectively capable of handling
hybrid dynamics, other clinical constraints and plant-model mismatch typically
present in such applications.
1.6 Thesis Outline
This thesis has been organized in five chapters. This Chapter was aimed at an intro-
duction to the thesis material. Chapters 2 and 3 carry discussion on modeling using
experimental data and in Chapter 4 control results are presented using simulations.
Chapter 5 ends with a summary and conclusion.
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Chapter 2 deals with methods of developing models using system identification.
Some of the issues with the nature of the experimental data and other theoretical
questions, typical to the application at hand, are discussed to arrive at a systematic
process of estimating dynamical models.
In Chapter 3, serves as an illustration of the developed methods on clinical data
for representative cases. We show cases of two participants in detail with discussion
on the available variables as inputs and outputs and on the quality of estimated
models. We also summarize the dynamical response for all the participants in the
clinical trial and on the effectiveness of this clinical trial.
Chapter 4 describes the control problem for an adaptive intervention. It in-
troduces the formulation for a hybrid model predictive controller [31]. It further
discusses the nominal and robust performance of the controller, using the estimated
model for one representative participant, under different disturbances and plant-
model mismatches.
We conclude our study in Chapter 5 with summary of methods and results from
system identification and hybrid model predictive control for naltrexone interven-
tion for FM. Finally, we present an outline for planned future work related to design
of informative clinical trial protocols, use of data-centric modeling on these infor-
mative data sets and the integration of these modeling approaches with a predictive
controller formulation as per clinical requirements.
16
Chapter 2
ESTIMATING PARSIMONIOUS MODELS: THE METHOD
2.1 Overview
Modeling for complex biological systems is a difficult and complicated process.
For example, in some areas like behavioral science the exact underlying cause-
effect relationship may not be fully understood through first principles, and hence
we can significantly benefit from building models using experimental data. We
take inspiration from the large number of engineering applications modeled using
system identification techniques [39]. We propose a similar framework for identi-
fying a parsimonious dynamical systems model for the effect of naltrexone on FM
symptoms.
Our modeling effort in this thesis can be summarized as follows: Since the
mechanism of the disorder is not understood, we rely totally on an empirical ap-
proach based on experimental data to build models. We apply prediction-error
methods to estimate a parametric model which can be best describe the output vari-
ance. The aim is to build low order models which can best describe the dynamics of
the effect of drug and other external factors on a symptom of interest. We perform
a single subject analysis where data for each participant is analyzed individually.
These models can then be used by a controller to assign dosages in an optimized
intervention.
One of the important issues in data analysis from human subject research and
particularly from clinical trials has been on the focus on a single subject vs multiple
subject analysis. From a perspective of adaptive interventions, our focus has been
on performing a single subject analysis. In a single subject analysis, the participant
is considered as a whole experiment in itself and we analyze the changes in symp-
toms (if any) reported due to drug intake, where as in multiple subject analysis, the
combined response of all participants are noted. For complex biological systems,
finding a common model explaining all observations for a population is possible
only when all the dynamics are understood. Hence when the modeling techniques
are used on multiple participants to estimate a common model, the model uncer-
tainty can be assigned to the unpredictable behavior of participants and such uncer-
tainty bound is generally more than that obtained from single subject analysis [40].
Also, some unusual participant response can be classified as outliers; there can also
be a large amount of uncertainty in measured data across the participants (e.g, when
participants are asked how they feel which is difficult to quantify) thus reducing the
merit of a multi participant model.
Dynamic modeling of the naltrexone intervention for FM is discussed in two
chapters. First, in this Chapter 2, we discuss about the nature of data collected from
clinical trials and then the methods, issues and challenges in system identification.
Some of the key concepts in Chapter 2 are explained using real data from clinical
trials. In Chapter 3, we describe a detailed application of the method to some rep-
resentative cases and provide a summary of results for all participants. The rest of
this chapter is organized as follows. In Section 2.2, we talk about the clinical trial
of naltrexone for reducing FM sysmptoms with a description of the variables asso-
ciated with the disorder which are measured in the trial. In Section 2.3, we discuss
the classification of variables as inputs and outputs for the dynamical model. In
Section 2.4, we summarize the modeling method which has been discussed in de-
tail in following sections: in Section 2.5 we discuss about parametric identification
and models structures, in Section 2.6 we discuss the importance of preprocessing
of data and in Section 2.7, we discuss the continuous model and its significance
to classifying participants as responders and non responders. In Section 2.8, we
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present a discussion on issues related to model validity particularly in relation with
clinical trials. We conclude the chapter with Section 2.9 where we present various
approaches to select inputs for model estimation.
2.2 Clinical Trial of Naltrexone Intervention for Fibromyalgia
Clinical trials are designed to test the hypothesis related to health interventions. In
accordance with the scientific method to prevent bias, the effect of the intervention
component under consideration, e.g. drug, is compared using an experimental con-
trol (e.g., placebo). Further, these studies can be developed as a single blind study
(where an individual subject does not know whether they are being administered
drug or placebo at given instant of time but the experimenter has that knowledge)
or as a double blind study (where both an individual subject and the experimenter
do not know whether the pill being administered is drug or placebo). It should be
noted that the single blind study can result in an experimenter’s bias. A crossover
design is also generally employed, if possible, where participants receive both treat-
ments and hence act as their own control (they take both drug and placebo). This
approach primarily reduces the errors caused by extraneous variables and does not
rely on large number Npar of subjects. Hence such studies are more optimal in
terms of statistical efficiency [41].
As the exact nature of FM still remains largely unknown, there have been var-
ious efforts to diagnose and treat this disorder. Depending how a researcher sees
the cause/mechanisms for the symptoms, there have been experiments with vari-
ous drugs. At present, there are three FDA (US Food and Drug Administration)
approved medications for FM [42] but these treatment(s) cannot be still used as a
standard clinical method because either patients just do not respond or they suffer
from side effects. Hence, the treatment of FM remains as an open area for ac-
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tive research. The aim of clinical trials for FM is two fold : to test the validity of
the pharmacological hypothesis and to get an insight into the exact mechanism by
which the disorder works by observing the drug response. First, the medications or
potential drugs have to tested for effectiveness, purity and other factors on animal
models. Naltrexone and its low dose version used in this study are already tested
and approved medications by the FDA for treating certain illnesses like alcoholism
[43]. Second, the length of the trial has to be established based on the hypothe-
sis/evidence of mechanism of pharmacological dynamics. As stated in [10] and
[44], it is expected that naltrexone works slowly on a day-by-day basis and peak
effect is expected somewhere around 28-30 days for participants responding to this
drug. Hence these studies are designed for as long as 22 weeks to incorporate all
the expected dynamics.
Detailed information on this clinical trial can be found in Younger et.al [10].
This trial was carried out in two stages: the first study was conducted as initial or
pilot study using 10 participants and the second study was conducted as a full study
on 30 participants with a longer protocol. The pilot study was designed as a placebo
controlled, single blind, crossover design where as the full study was designed as a
randomized placebo controlled, double blind, crossover study.
The schedule and time line used for clinical trial (both pilot and full study) is as
follows:
• Baseline : During this phase participants do not receive any kind of medica-
tion. The responses noted during this period will represent the “normal” or
baseline status of FM symptoms. The duration of the baseline period is of
two weeks for both the pilot and full study.
• Drug/Placebo : During this phase, participants receive either drug or placebo
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as a part of blind study. In the pilot study, the protocol is designed such
that first placebo is administered and then drug. The full study follows the
approach where the participants are randomized to be assigned either drug or
placebo for a total participant count of 30. Hence, only the 15 individuals
who received placebo first have a design that is similar to the pilot study.
• Washout : During this phase, all kinds of medications are stopped and the
aim is to observe the symptoms after cessation of either drug or placebo. The
washout period consists of two weeks or more.
In order to assess the effectiveness of the intervention, we are interested in noting
the changes, if any, in the symptoms closely associated with FM. Since many of
the symptoms are behavioral or pathophysiological in nature and there is currently
no test per se to detect or quantify FM, we rely on the responses entered by par-
ticipants’ judgment based on self-reports. Participants completed daily reports of
symptom severity using a hand held computer and visited lab every 2 weeks for
tests of mechanical, heat, and cold pain sensitivity. Some of the aspects of data
collected from this trial will now be discussed.
2.2.1 General Description of Variables
We begin by grouping the data available from trial in to two broad categories :
• Self reported data : The participants enter their responses daily on a scale of
100 on various symptoms related to FM. These variables are based on self-
reports and are rooted in behavioral science rather than being measured in
real physical parameters.
• Physically measured data: The participants visited a clinic every 14 days to
undergo a quantitative sensory testing to obtain pain thresholds induced by
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the application of mechanical pressure, heat and cold. These variables are
measured using physical quantities like ◦C.
The daily diary data acts as the source of primary information on the clinical
trial for allowing the experimenter to judge how well the drug affects the symptoms.
The sensory testing data is used more in secondary role, like for validating the
inferences.
In addition to grouping according to sources of data, we have two sets of data
from clinical trials performed. The pilot study follows a Placebo-Drug protocol
with total trial length of 98 days and the full study follows both Placebo-Drug as
well as Drug-Placebo protocols with a total trial length of 155 days. The data from
daily diary (qualitative data) is sampled time T = 1 day and physically measured
data (quantitative data) is sampled at T = 14 days. The questions that form a part
of the daily diary reports are shown below. The questions from 1−16 are entered
on a scale of 0− 100 where 100 is the maximum corresponding to that variable;
questions 17− 20 are entered in as binary variables (yes or no). These variables
(with the common name with which we will address them further) listed below
describe more or less the typical symptoms experienced in FM.
1. How would you rate your general satisfaction with life today? [Life]
2. Overall, how severe have your fibromyalgia symptoms been today? [FM
sym]
3. How would you rate your general level of pain today? [Pain]
4. What was your highest level of pain today?
5. How fatigued have you been over the day? [Fatigue]
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6. How sad, down, or blue have you felt today? [Sadness]
7. How anxious have you felt today? [Anxiety]
8. How stressed have you been today? [Stress]
9. How good has your mood been today? [Mood]
10. How much trouble did you have getting to sleep last night? [Sleep]
11. Overall, how well did you sleep last night? [Overall Sleep]
12. How clearly were you able to think and remember things today? [Think and
Rem]
13. Did you experience and bowel or gastrointestinal problems today? [Gastric]
14. Did you suffer any headaches today? [Headaches]
15. How well are you tolerating the medication? [Toleration]
16. Have you experienced any negative side-effects from the medication? [Side
effects]
17. Have you taken your capsule for tonight?
18. Did you take your capsule last night?
19. Did you experience any unusually stressful events today?
20. Did you have to take any other pain medication today?
Some of the variables from this data set can be re-organized for clarity and to
cut down on some redundant information. For example, we have two reports related
to sleep conditions: ‘How much trouble did you have getting to sleep last night?’
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and ‘Overall, how well did you sleep last night?’. We primarily use overall sleep
as the indicator for sleep quality. Similarly, as pain is the defining symptom of FM,
the responses for ‘fibromyalgia symptom severity and ‘average daily pain are more
or less similar for all participants and hence FM sym is the defining variable for
symptom severity.
Based on the questionnaire in the daily dairy data, we can make a couple of
important remarks before we move to the topic of dynamical modeling. First, the
response entered for questions 1−16 in range of 0−100 are based on behavioral
status of that participant as reported by them and these response, which are not
based on actual physical signals, can be misleading. Moreover, the response level
of one participant is not expected to match up with other participant. For example,
a pain report of 60/100 for participant A may not be the same for pain report of
60/100 for participant B because the thresholds for each individual may vary as
well as their assessments of the symptoms. It can be argued that all behavioral
characteristics have their origin in the complex neurobiology of the human body
and one might argue that it will suit best to measure the direct signals in the neural
pathway to best ascertain the observed condition(s). Again, as mentioned before,
such an approach is difficult, if not impossible, for a complex system. Secondly,
the discussion on first point reinforces our thinking of single subject analysis or an
idiographic approach as opposed to a common model applicable to all participants
or a nomothetic approach [6]. The use of experimental data and the validity of
proposed modeling procedure is highly applicable for a single subject analysis.
2.3 Dynamical Modeling
Traditionally in clinical trials, the effectiveness of the intervention is judged using
statistical methods [41]. The criteria used by Younger et al. to determine a response
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to treatment is a thirty point reduction in self-reported symptoms over placebo at
the conclusion of the trial [10]. Such an approach may not be very useful to build
models that have to be used in decision making scenarios, such as adaptive inter-
ventions, as they tend to reflect steady state behavior rather than critical transient
dynamics. Hence our approach to this problem is based on dynamical system the-
ory where we try to build models which can be used to best describe the dynamics
of the treatment by determining a time-dependent causal relationship between in-
puts and output. Further, this analysis can be used in a more detailed classification
of participants as per response to the drug. We use prediction-error methods [35] to
estimate a parametric linear time invariant (LTI) model. Although we lack substan-
tial a priori knowledge about the system, we can make some inferences about the
nature of the experiment, as discussed further.
Biological systems are characterized by complex interdependent components.
Systems such as the human body has evolved a complex internal compensation
system; in other words, an internal “controller” which tries to nullify any exter-
nal factors causing undesired change. This phenomena is known as homeostasis
or homeodynamics [45] which is implemented through the natural physiology of
the body like in regulation of blood glucose or sometimes through the immune
system, in case of infections. The feedback mechanism (both positive and nega-
tive), denoted by homeostasis, may result in cross correlation between endpoints
and unmeasured noise [38] collected from medical treatments and hence such ex-
periments can be classified, in a classical system identification sense, as closed loop
experiments. For example, in the case of FM there may be a relationship between
variables such that “output” affects “input” e.g., elevated pain condition may effect
anxiety levels although the existence of the feedback path is not clear. The feed-
back path can be through a controller internal to the participant or a causal function
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which maps variables.
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Figure 2.1: Linear Fractional Transform (LFT) model structure for given FM sys-
tem.
In Figure 2.1, we describe a general structure for this system observed for FM.
This representation of the system corresponds to a linear fractional transform (LFT)
representation where the two LTI systems are: P the plant and the controller block
K. We show how variables might react in such as system where variables can
be measured and unmeasured. Variables and blocks represented in the figure are
described as:
• P is the plant transfer function through which drug directly affects outcomes
under interest such as pain.
• u are the exogenous input signals acting on the system whose values can be
influenced by the clinician (e.g., through assigned dosages). These manipu-
lated variables are u ∈ {drug and placebo}.
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• d are the exogenous disturbance signals acting on the system whose values
cannot be adjusted by the clinician. e.g., d ∈ {stressful event}
• y are the outcomes of interest which are measured or assessed in the experi-
ment.
e.g., y ∈ {FM symptoms, overall sleep, fatigue,...}
• w are the measured and unmeasured input signals acting on the system through
the feedback path and does not include variables associated with u and d.
• z are the measured and unmeasured output signals acting on the system which
may include variables associated with y.
• K is the transfer function for the feedback controller which maps z to w.
The measured variables in u,d,w can be grouped as inputs and measured vari-
ables in y,z can be grouped as output to estimate a dynamical model using system
identification. The three approaches for closed loop identification can be described
as:
• Direct Method. It assumes no knowledge of feedback loop and treats the
problem as an open loop problem.
• Indirect Method. It assumes complete knowledge of the feedback mechanism
K and is used in the estimation method to obtain models.
• Joint Input-Output Method. The feedback path is assumed to be of certain
structure and then use experimental data to infer the feedback transfer func-
tion and estimate the plant.
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Clearly, the indirect approach is not possible due to lack of information. The
third approach also assumes a priori information about the structure of feedback
which is not known. Hence we approach this problem as in classical system identi-
fication by considering it as an open loop system and solve using direct methods. It
should be noted that methods like correlation analysis and subspace identification
may fail in closed loop whereas prediction-error methods work well with enough
parameters [35] and hence we use it in further analysis.
Section 2.2 lists out the variables associated with the naltrexone trial. Looking
at the Figure 2.1, we note that some of the variables associated with the study
may preexist before the administration of either drug or placebo i.e. during the
baseline period like anxiety and sadness and hence can be classified as both w and
z. These variables may show changes on application of these external inputs and
other external disturbances. The transfer function type mathematical models are
used to define the relationship between the input(s) and output(s) from the available
measured variables in the clinical trial.
2.3.1 Outputs
We are primarily interested in understanding how drug affects various FM symp-
toms during the naltrexone intervention and hence the core symptoms of this dis-
order like pain, fatigue, sleep disturbance, bowel abnormalities and cognitive dys-
function can be classified as outputs or dependent variables. The pilot study [10]
classifies FM symptoms (question 2) as primary outcome, which we use as the
principal output for our analysis. We also consider overall sleep and fatigue as out-
comes of interest in this study. In behavioral sciences, there is increasing effort
in understanding the relationship between a primary variable and a mediator vari-
able - an output that is an intermediate to another output of interest [46] e.g., the
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relationship between pain and sleep or fatigue is clinically very relevant.
2.3.2 Drug and Placebo as an Input Signal
Drug and placebo are classified as the primary inputs in the analysis. They are
added externally to the system and can be manipulated by, and are of interest to, the
user. In system identification, the quality of models estimated is highly dependent
on the richness of the information content in the data which is a function of the per-
sistence of excitation in the input signals [35]. Extensive amount of work has been
done in past (Rivera et al. [47, 48]) on issues of input signal design to maximize the
information content in experimental data under test conditions. In typical system
identification scenario, the unknown system under analysis is excited by an input
signal specifically designed to excite the frequencies required for further analysis.
The input signal can have significant influence on identification results. Specifically
for control purposes, we are interested in frequency information content useful to
the controller [49]. Typical inputs seen in the literature are white noise, step and im-
pulse inputs, random and pseudo random binary sequence (PRBS) and multisines.
It is to be noted that the term input signal used here is with respect to an external
signal which can be designed by an user and does not apply to all the inputs to a
system.
In case of clinical trials in general, the input signal (i.e, which can be manipu-
lated by the user) available is in the form of a step function (or a rectangular pulse
function). This can be realized when we look at how the protocols are designed; the
aim is to test the effectiveness/usefulness of the intervention (using, say, a drug in
this example) and so a clinical dosage is fixed for the period of trial. In other words,
the participants receive a fixed dosage for a stipulated time period which translates
into a rectangular input - with a low to high pulse input and a high to low pulse
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input as shown in Figure 2.2.
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Figure 2.2: Typical external input(s) in a clinical trial; In this figure two independent
inputs are shown as Drug (solid,blue) and Placebo (dashed,red).
The possibility of different protocol design on lines of more typical input sig-
nals like PRBS is not common in clinical trials and has not been carried out in this
work. This issue of input signal design, however, presents itself with problems like
clinical constraints and restrictions for example, it may take time for some drug
to show effect and hence the dosage level has to be maintained for a time period
as per the pharmacodynamics. Also in typical system identification experiments,
the excitation is applied periodically to get a large sample size where as in typical
clinical trials only one cycle of experimentation is followed. Also, the step input
emphasizes low frequencies or steady state behavior. Since in this work we con-
duct a secondary analysis of data, the main identification problem that needs to be
considered is that of estimation.
2.3.3 Other Inputs
As shown in Figure 2.1, we note that in addition to drug there are other variables
affecting an output of interest (e.g., pain). Hence we add the variables excluding
those we classified as outputs as additional inputs like anxiety, stress and mood are
added to these primary inputs to improve the variance of estimated models hence
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improving the overall % fit. These inputs are measures which were noted as sec-
ondary outcomes in the pilot study [10].
2.3.4 Is There Feedback in Data?
It may be important to detect feedback between variables to truly classify a variable
as an exogenous variable specially when we have access only to the experimental
data. Asides from gaining system knowledge, the presence of feedback is impor-
tant from a statistical point-of-view for system identification. Classical analysis
approaches the idea of feedback from the notion of causality e.g., if
y(t) = f (u(ti−1,i−2,...1))+ν(t) (2.1)
then presence of feedback would imply that
u = g( f (y(ti−1,i−2,...1)))+ω(t) (2.2)
where ν,ω are random noise and f ,g are forward and feedback transfer function re-
spectively. Hence if the finite impulse response (FIR) causal and non causal model
describing the process y in terms of u are same, then there is no feedback. Conse-
quently this means that if a non causal FIR model is chosen to represent the impulse
response, then significant parameter value for negative lags would imply presence
of feedback. Although this is an useful operational technique, it works under the
assumption that impulse response can always be estimated [50, 51]. Another ap-
proach is a statistical method where using innovation representation for joint pro-
cess, a hypothesis test (χ2 test) is conducted to determine there is no feedback from
a particular set of input and output [52].
2.4 General Method for System Identification
The daily diary data is used to estimate a dynamical systems model. The modeling
process undertaken in this study can be summarized in three subparts as follows:
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1. Data preprocessing. Initially the data is pre-processed for missing entries using
a simple mean of immediate neighbors imputation method. To reduce the
high frequency content in the time series data, a three day moving average is
applied.
2. Discrete-time parametric modeling using prediction-error method. The filtered
data is then fitted to a parametric model using ARX model structure. The pro-
cedure here is to begin with drug and placebo as inputs, then add additional
input variables (like anxiety, stress and mood) to improve the goodness of
fit. While increasing the number of inputs improves the overall fit of the
model, an exceptionally high fit does not necessarily correspond to a predic-
tive model; consequently, the set of input variables that we feel appropriately
describes the data across all participants must be determined. Having es-
timated models for these inputs, unit step responses (corresponding to the
output change for a magnitude one step change in the input) can be obtained
and interpreted.
3. Simplification to a continuous time model. The step responses from the discrete-
time parametric model are fit to a low-order continuous models that conform
to 1st and 2nd order differential equations. Gain, time constants, and settling
times for each input and participant are noted. Based on these methods, we
classify the participants on basis of their response to drug in Section 2.7.
The parametric identification forms the essence of our modeling discussion and
hence has been discussed in the following section. Items 1 and 3 are discussed in
the sections following parametric identification.
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2.5 Parametric System Identification
The procedure for system identification can functionally classified as:
1. Experimental or input design
2. Data collection
3. Model structure (parametric (e.g., ARMAX) or non parametric (e.g., Fre-
quency response))
4. Model estimation
5. Model validation
Since the experimental design and data collection were fixed during the clinical
trial phase, the system identification exercise in this work has been limited to items
3 through 5 only. Also as this model has to be used in a control setting, our focus
has been on identifying parametric models with information relevant for control. In
the process of modeling the dynamics of naltrexone intervention, we are faced with
three important questions:
• Which model structure works best for the intervention?
• How can we reduce the bias and variance of estimated models?
• Since we have so many inputs at hand, how can we avoid the problem of over
parametrization?
2.5.1 Prediction Error Methods
Prediction error methods are among the most popular methods developed in system
identification literature. This approach is based on minimization of certain cost
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function of observed data and parameter θ using regression methods. The variable
nomenclature as adopted in this section is taken from system identification literature
(e.g. [35]). Consider a set of discrete time parametric model structure as a function
of θ :
y(t) = p˜(q,θ)u(t)+ p˜e(q,θ)e(t) (2.3)
where p˜(q,θ) is the plant model, p˜e(q,θ) is the noise model, q is the forward shift
operator and t is a discrete time index [35]. Based on the experimental data set
Z containing the set of data {y,u} of length N, we can form a cost function of
the prediction errors, VN , which on minimization will converge under asymptotic
conditions. For mean square error type prediction error estimate, we can write
ˆθN = arg min{VN(θ ,ZN)} (2.4)
=
1
N
N
∑
t=1
e2(t,θ) (2.5)
where ˆθN is the estimated parameter vector and e(t) is known as the residual or the
prediction error calculated as:
e(t) = p˜e(q,θ)−1(y(t)− p˜(q,θ)u(t)) (2.6)
p˜, p˜e can be alternatively written in parameterized form using polynomials (and re-
moving the need for use of θ , see Table 2.1) and hence in representing a dynamical
system, the first step is to find an appropriate structure of the model. The hypothesis
is that the chosen model structure should be able to capture the useful dynamics of
the excited system. Keeping track of our aim of modeling to develop a parsimo-
nious model for the system using experimental data, we represent the common para-
metric methods used in system identification literature as following: ARX (Auto-
Regressive with eXogeneous inputs), ARMAX (Auto-Regressive Moving-Average
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with eXogeneous inputs), FIR (Finite Impulse Response), BJ (Box-Jenkins) and
OE (Output Error). The general structure describing these models can be written as
in lines of equation 2.3 as:
A(q)y(t) =
B(q)
F(q)
u(t −nk)+ C(q)D(q)e(t) (2.7)
where A,B,C,D and F are causal polynomials in q defined as
A(q) = 1+
na∑
1
aiq−i (2.8)
B(q) =
nb∑
1
biq−i+1 (2.9)
C(q) = 1+
nc∑
1
ciq−i (2.10)
D(q) = 1+
nd∑
1
diq−i (2.11)
F(q) = 1+
n f
∑
1
fiq−i (2.12)
Table 2.1: Tabulation of five PEM structures.
Method p˜(q,θ) p˜e(q,θ)
ARX B(q)A(q)q
−nk 1
A(q)
ARMAX B(q)A(q)q
−nk C(q)
A(q)
FIR B(q)q−nk 1
BJ B(q)F(q)q
−nk C(q)
D(q)
OE B(q)F(q)q
−nk 1
First clear distinction which can be made based on the structure of these models
is the set which uses different parameters to define the plant and noise models, like
the BJ method, and the other set, such as the ARX method, which uses common
parameters to define both the plant and noise dynamics. This means that for bias
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free estimation in the case of ARX models, for example, we need accurate estima-
tion of both p˜ and p˜e. By setting C(q),D(q),F(q) to unity as described in equation
2.7, we get the ARX model structure which contains only polynomials A(q) and
B(q). When compared to the ARX method, ARMAX structure uses extra polyno-
mial C(q) to define the noise model. It can be noted that the noise dynamics (or
the poles of estimated noise model) are same to that of the plant model. FIR mod-
els are used to define the impulse response of the linear time invariant system. A
critical condition that is evident in this scenario is that the FIR model order can be
significantly large when we need to capture the full dynamics. Although they do
not carry much weight in terms of control relevant identification but they do give an
unique insight into the system. In case of last two model structures of BJ and OE,
they are generally selected only if the previous structures do not give a satisfactory
result. For BJ, we have to permutate with four parameters (nb,n f ,nc,nd,nk) before
converging to a useful model.
On topic of computation, ARX models (and FIR models) estimated with the
quadratic criteria function reduces the optimization problem to linear least squares.
This means that we are guaranteed a unique minimum (global) solution for our
estimation problems. For other model structures, viz. ARMAX, BJ and OE, the
optimization problem is nonlinear in nature and the solution is calculated using an
iterative optimization scheme with no guarantee of global convergence; however,
robust and reliable computation methods (e.g., system identification toolbox, MAT-
LAB) are available.
When answering the question on which structure works best for the naltrexone
intervention , we also keep in mind that we have a limited number of data samples
or limited duration of identification test. This is a particular issue in case of FIR
models where finite, noisy data results in bad estimates (using correlation method,
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for example) and where only probabilistic bounds can be derived for estimated
models [50]. Upon experimentation, we find that ARX and ARMAX models gave
sufficiently good fit to output data in simulation and hence we will use these struc-
ture further in our analysis while keeping in mind the variance issues with these
structure in presence of significant noise.
Following from equation 2.7, the ARX structure is a linear difference equation
that relates the single input u(t) to the single output y(t) as follows:
y(t)+a1y(t−1)+ ...+anay(t−na) = b1u(t−nk)+ ...+bnbu(t−nk−nb+1)+e(t)
(2.13)
where y(t) is the output and is predicted using delayed inputs and output variables.
ARX models are represented as ARX [na, nb, nk] where, from systems point of
view, na is the number of poles, nb is the number of zeros plus one and nk as time
sample before inputs affects the output in discrete time systems (equals one when
no time delay). ARX models can otherwise be represented for multi-input case in
discrete time polynomial form as:
A(q)y(t) =
nu∑
i=1
Bi(q)ui(t −nki)+ e(t) (2.14)
where nu represents the number of inputs, na, nb and nk are model orders, e(t)
is the prediction error, and A(q) = 1+∑naj=1 a jq− j and Bi(q) = ∑
nbi
j=1 b jq− j+1 are
polynomials in q.
2.5.2 Issues in System Identification
After deciding upon a model structure (i.e. ARX model), we divert our attention to
the process of model estimation. The mean square error of the parameter estimate
can be represented as
MSE( ˆθN) = (Bias( ˆθN,θ0))2 +Var( ˆθN) (2.15)
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where θ0 is the true parameter. Hence the principle error in system identification
arise from following two sources:
• Bias errors: Bias errors are systematic errors due to the use of an incorrect
model structure for generating models; in other words a correct model struc-
ture is a requirement for bias free estimation.
• Variance errors: Variance errors are from noise in the data. These errors
show up as variance in the parametric estimate. This error is irrespective of
correct/incorrect model structure chosen. We also group error due to mea-
surement noise into this.
We will address these important points and discuss how these error can be sys-
tematically handled.
2.5.2.1 Bias Errors
For illustration, consider a system described by one manipulated input u(t) (e.g.,
drug), one measured disturbance input d(t) (e.g, anxiety) and noise ν(t) with plant
and estimated models as follows:
y(t) = p(q)u(t)+ pd(q)d(t)+H(q)ν(t)
= p˜(q)u(t)+ p˜d(q)d(t)+ p˜e(q)e(t) (2.16)
where p and p˜ are transfer functions corresponding to true plant and estimated plant
respectively, H is the real noise model and p˜e is the estimated noise model. We use
a suitable filter to ‘prefilter’ the real signals and hence we can define yF(t) as the
filtered version of the real signal y and similarly, uF(t),dF(t) are the filtered input
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and disturbance signals respectively of the real signals u(t) and d(t).
yF(t) = L(q)y(t) (2.17)
uF(t) = L(q)u(t) (2.18)
dF(t) = L(q)d(t) (2.19)
where L(q) is the filter transfer function. To keep the analysis in terms of real
measured signals, we explicitly mentioned the filter in further definitions.
The one-step-ahead prediction error for this system can be written as
eF(t) = p˜e(q)−1(yF(t)− ( p˜(q)uF(t)+ p˜d(q)dF(t))) (2.20)
= L(q) p˜e(q)−1(y(t)− ( p˜(q)u(t)+ p˜d(q)d(t)))
The prediction error power spectrum can be directly related to the prediction error
using Parseval’s theorem (sum or integral of square of a function is equal to sum or
integral of square of its Fourier transform) giving frequency domain insights into
the sources of bias errors. Using the discrete version of Parseval’s theorem:
∞
∑
n=−∞
|x[n]|2 = 1
2π
π∫
−π
|x f |2dω (2.21)
where x is the discrete series and x f is the discrete time Fourier transform. Using
the definition of the power spectral density and extending for the prediction error,
we can write
1
N
N
∑
t=1
e2F(t) =
1
2π
π∫
−π
ΦeF (ω)dω (2.22)
Based on equation 2.16, we can state the following definition.
Definition 1. The prediction error spectrum (ΦeF ) for a single input, single distur-
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bance and single output system can be written as
ΦeF (ω) =
|L(q)|2
| p˜e(q)|2{|p− p˜|
2Φu(ω)+ |pd − p˜d |2Φd(ω)
+2Re((p− p˜)(pd − p˜d)∗)Φud(ω)+ |H|2σ2ν} (2.23)
where ν is assumed to be uncorrelated with u and d.
Proof. The equation 2.23 can be derived by using the corollary that a cross spec-
trum between two signal can be defined as the Fourier transform of the cross co-
variance function:
Φu1u2(ω) =
∞
∑
τ=−∞
Ru1u2(τ)e
− jτω (2.24)
and using the expectation operator, we can define the cross covariance as
Ru1u2(k) = E[u1(t)u2(t + k)] (2.25)
where u1(t),u2(t) is the given jointly quasi stationary. Similar result is true for the
case of spectral density of a quasi stationary signal using auto covariance as
Ru(k) = E[u(t)u(t+ k)] (2.26)
Also note the following corollaries:
Φsn(ω) = G(e jω)H∗(e jω)Φuv(ω) (2.27)
Φsn(ω) = Φ∗ns(ω) (2.28)
where u,v are the inputs to transfer functions G,H and s,n are the respective out-
puts.
Now consider a system as described in 2.16. The one step prediction error can
be rewritten using the covariance of eF(t) and on assuming ν is uncorrelated with
all inputs. Using the above corollaries, we can arrive at the result.
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Definition 2. The general filtered prediction error spectrum for a system with n
input plants and m disturbance plants
y(t) = p1(q)u1(t)+ ...pn(q)un(t)+ pd1(q)d1(t)+ ...+ pdm(q)dm(t)+H(q)ν(t)
(2.29)
= p˜1(q)u1(t)+ ... p˜n(q)un(t)+ p˜d1(q)d1(t)+ ...+ p˜dm(q)dm(t))+ p˜e(q)e(t)
(2.30)
and when the filtered one-step-ahead prediction error is
eF(t) = L(q) p˜e(q)−1(y(t)− ( p˜1(q)u1(t)+ ... p˜n(q)un(t)+ p˜d1(q)d1(t)+
...+ p˜dm(q)dm(t))) (2.31)
can be written as
ΦeF (ω) =
|L(q)|2
| p˜e(q)|2{|p1 − p˜1|
2Φu1(ω)+ |p2 − p˜2|2Φu2(ω)+ ...
+ |pn−1 − p˜n−1|2Φun−1(ω)+ |pn − p˜n|2Φun(ω)
+ |pd1 − p˜d1 |2Φd1(ω)+ |pd2 − p˜d2 |2Φd2(ω)+ ...
+ |pdm−1 − p˜dm−1 |2Φdm−1(ω)+ |pdm − p˜dm |2Φdm(ω)
2Re(p1 − p˜1)(p2 − p˜2)∗Φu1u2(ω)+ ...
+2Re(pdm − p˜dm−1)(pdm − p˜dm−1)∗Φdmdm−1(ω)+ |H|2σ2ν} (2.32)
where p1...pn are the n input plants, pd1 ...pdm are the m disturbance plants and ν
is assumed to be uncorrelated with all inputs and disturbances.
Let us analyze the sources of bias by using 2.23 as our reference. It is possible
to obtain insights into how input power, model structure, cross-correlation between
signals, and other factors can influence the goodness-of-fit in the identification pro-
cess as follows:
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• Model structure. An incorrect plant model structure corresponds to the |p− p˜|
term being non-zero and results in an asymptotic bias. Similarly incorrect
structure p˜e for the noise model will result in a bias (though this term acts
like a scaling factor).
• Input signals. In Section 2.3.2, we discussed about external signals like drug
and placebo which are administered by the user and other exogenous distur-
bance signals which are added to improve the variance of estimated models.
In all, input signals must show sufficient power (See Figure 2.4) in the fre-
quency range of interest. As in this problem we are not designing input sig-
nals, we limit our inference of estimated models to the bandwidth provided
by the available signals.
• Prefiltering. Prefiltering is used to change the noise characteristics of the data
without changing the transfer function relationship in the estimated models.
The prefilter can be used as a weight and hence as a means of providing
emphasis on frequency intervals of importance to the problem. In this work,
a three day moving average filter L(q) is applied as the smoothing filter. It
is equivalent to a low pass filter expressed in finite impulse response filter as
discussed in Section 2.6.
• Input cross correlation. Since various variables are measured in the experi-
ment, the procedure is to choose inputs which have minimum cross spectra
(Φud(ω)) to reduce the bias error. Better insight can be gained from the daily
reports by studying the cross-correlation between variables. We can use cross
correlations to better understand the relationship between variables which are
exogenous. For instance in Fig. 2.3, the headache and gastric variables have
high degree of cross-correlation, and are also correlated with the FM symp-
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Figure 2.3: Cross correlation between two variables for 10 lags (shown with 2
standard error bounds) for a representative participant.
toms output. Adding them as inputs did not yield good estimates. In compar-
ison, anxiety and mood variable are essentially uncorrelated and offer good
estimates when included as inputs.
Since power spectra of input signal significantly effects the result from system
identification, we estimate the possible frequency range of purely exogenous signals
like drug which can be specified by the user. The pulse input signal, as shown in
Figure 2.2 can be written as following:
u(t) =
⎧⎪⎨
⎪⎩
A if t1 ≤ t ≤ t2
0 otherwise
(2.33)
where t1 is the first day, t2 is the last day and (t2 − t1)/2 is the center of the pulse.
The signal can be imagined as two successive step inputs in opposite directions and
separated by a time delay. Let the original drug signal shown in Figure 2.2 be a
rectangular pulse of width β , height A and is centered at C. This can be represented
mathematically as follows: assume that the rectangular pulse starts at origin and
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hence is centered at β/2. We can rewrite u(t) and its Laplace transform as
u(t) =
⎧⎪⎨
⎪⎩
1 if 0 ≤ t ≤ β
0 otherwise
(2.34)
U(s) =
A(1− e−β s)
s
(2.35)
Now, this signal can then be time shifted by C − β/2 such that the center of the
pulse is at C (corresponding to the original signal). Hence, we can write
U(s) =
A(1− e−β s)
s
e−(C−β/2)s (2.36)
Similar to a single step, this function will emphasize low frequencies. The infor-
mative data sets are related to the persistence of excitation in the input signals.
Roughly speaking, the persistence of excitation gives an insight into the order of a
model that can be estimated in an unambiguous way (See [53]). As per Ljung [35],
Soderstrom [36], a signal u(t) is said to be persistently exciting of order n per if the
covariance matrix is positive definite. In relating this concept to the input spectrum,
the persistence of excitation means that Φ(ω) is non zero for at least nper distinct
frequencies in −π ≤ ω ≤ π .
Definition 3. A quasi-stationary input u(t) is persistently exciting of order n per if
the matrix
ˆR =
⎛
⎜⎝ Ru(0) · · · Ru(nper −1)
Ru(nper −1) · · · Ru(0)
⎞
⎟⎠ (2.37)
is positive definite
The Figure 2.4 shows the power spectra for selected inputs from a representative
case. It can be noted that most of the exogenous signals are persistently exciting in
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range up to 0.6 radians/day. The magnitude difference between drug and placebo
and the other inputs is due to the different units of measurement that are used. When
used as inputs, these signals were found to of order nper = 26. When inferring
estimated standard deviations from parameter covariance matrix, we keep in mind
the limitations up to excited frequencies only [54].
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Figure 2.4: Power spectral density of variables associated with naltrexone interven-
tion (as shown in Figure 1.1) using Welch’s method with Hamming window.
2.5.2.2 Variance Error
We now come to our second and most important question : How to reduce the
variance of estimated models? In a classical sense using the asymptotic results, the
variance is affected by the number of model parameters, signal-to-noise ratio and
the length of the data set as shown below:
Cov( p˜) n
N
Φν(ω)
Φu(ω)
Cov( p˜e) nN H(e
jω) (2.38)
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where, as before, n is the number of parameters and N is the duration of the identi-
fication test. As N is fixed in this experiment, we can vary only the model orders.
It can be noted that the variance of the plant parameter estimates can be affected
by input signals where as the variance of estimated noise model is independent of
inputs [35]. The equation 2.38 is a valid approximation under under asymptotic
conditions in an open loop operation although they may differ for system under
consideration or under finite date samples [55, 56]. Although this case under con-
sideration cannot be classified exactly as open loop, the results still hold their valid-
ity. As we do not have control over experimental design, the variance of the output
can be better described by adding more inputs or in other words by estimating a
multi-input single-output model. This issue has been discussed using data from a
representative case. Our aim is to model the effect of drug on designated output
e.g. FM symptoms. After choosing a starting model structure and order (say ARX
[221]), we notice the variance of estimated model as well as we simulate the model
to observe the percent fit. The first model is based on drug as input and FM sym as
output. The percentage fits can be seen in Figure 2.5. Adding extra input to improve
the quality of our model can be thought of in two ways. First, from the analysis of
FM disorder and symptoms associated with it point to the fact that changes in stress
or anxiety levels contribute to elevated pain levels and/or worsened sleep patterns.
So intuitively speaking, adding extra inputs define our cause-effect relationship in
a much better way that what can be just described by drug-FM symptoms model.
From a statistical view, it can be shown that adding extra inputs results in improved
covariance of the parameter estimate under the assumption that they are indepen-
dent [57]. Also since ARX and ARMAX model structures use common parameters
in plant and noise models, the net benefit of adding these extra inputs is much
stronger in ARX/ARMAX than other structure which use independent parameters.
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Table 2.2: Tabulation of parameter estimates with standard deviations for partici-
pant 5.
# A dA B dB
1 1 -1.2163 0.2326 0 0.0975 0.0983 -19.2805 18.3987 7.8729 7.7681
2 1 -1.1755 0.2170 0 0.0949 0.0949 -7.6722 7.5010 8.7654 8.611923.8433 -20.7684 8.6107 8.5827
3
1 -1.1183 0.2368 0 0.0971 0.0924 -8.5325 7.9869 8.7576 8.5380
15.0847 -7.7456 10.5871 11.5068
0.2712 -0.1020 0.1131 0.1119
4
1 -1.0265 0.2148 0 0.1001 0.0878 -0.4938 -0.0931 1.9002 1.9076
19.7477 -11.4083 10.1713 10.8634
0.1451 -0.0195 0.1130 0.1116
0.4780 -0.0915 0.1633 0.1739
5
1 -1.0061 0.2001 0 0.1011 0.0885 -1.2124 0.7326 1.9540 1.9797
15.5084 -6.6184 10.5228 11.2836
0.1469 0.0219 0.1128 0.1151
0.4952 -0.0499 0.1694 0.1770
-0.0917 0.0739 0.0670 0.0665
This result reinforces our choice of selecting ARX/ARMAX models over other
model structures as we are dealing with a typical multi input single output type
scenario. Although input are not completely independent in this work, we see the
benefit of using multi input type models in Table 2.2.
Exact methods of choosing the inputs are discussed in the next section. Al-
though better fit to experimental data is desired, that cannot be the only criteria to
be used to judges the usefulness of the estimated models [58]. The ‘model fit’ ter-
minology used in this thesis points to the amount (percentage) of output variance
explained by the model as:
model fit (%) = 100×
(
1− ||(yˆ− y)||||(y−μ(y))||
)
(2.39)
where yˆ is the simulated output, μ is the mean operator and y is the measured
output. Improvement in estimated models can also be analyzed by observing the
step response of each models. The reliability of estimated models is discussed in
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(a) Model 1 - Input = {Drug}Output = {FM sym}
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(b) Model 2 - Inputs = {Drug, Placebo} Output =
{FM sym}
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(c) Model 3 - Inputs = {Drug, Placebo and Anxi-
ety} Output = {FM sym}
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(d) Model 4 - Inputs = {Drug, Placebo, Anxiety,
Stress} Output = {FM sym}
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(e) Model 5 - Inputs = {Drug, Placebo, Anxiety,
Stress, Mood} Output = {FM sym}
Figure 2.5: Model fits estimated seven models for Participant 5 from the pilot study.
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Section 2.8.
Lastly, since there are inherent noise in the data collected in any experiment,
we try to remove the high frequency content of the data using low pass filtering.
Besides, the estimated noise model is supposed to capture the noise dynamics and
which can be more accurately modeled if noise properties like noise covariance
matrix are know a priori. In this work, no such information was available. Esti-
mating these properties from input-output data can be pursued although there is no
certainty that they will yield good estimates [59]. On a side note regarding noise
models, it can be noted that the used models in this work (ARX, and also ARMAX)
use the same parametrization for poles as in the plant model. As was noted earlier,
using more sophisticated parametrization (ARX to ARMAX) for the noise model
did not yield any significant improvements.
2.6 Preprocessing of Data
Before using the experimental data, it has to be preprocessed to be used for system
identification techniques for two specific reasons: a) to account for missing data
b) prefiltering to emphasize the bandwidth of interest . In general, data from clinical
trials presents itself with unique challenges in unusual errors in measurements due
to missing data and other anomalies. These two broad deficiencies in this data set
are discussed now.
• Missing Data. The daily diary data is entered by the participants every night
before they go to bed. Sometimes, the entries are not made on time so on a
scale of 155 days (e.g., in case of full study), there are anywhere from 5−35
days missing. On days when the daily dairy was filled, participants tend to
miss answering some questions and hence rendering that data point as Not-
a-Number (NaN). For handling the missing data, we approach this problem
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as a problem of interpolation. Before interpolation, we make sure that all
NaNs are taken care by using techniques such as imputation. We average the
nearest neighbors and use that value in place to missing data.
x[n] =
x[n−1]+ x[n+1]
2
(2.40)
After imputation, based on the daily data entries we can note exact dates on
which the entries were made and since the start and end dates on the trial are
known, dates with missing entries can be noted. It is assumed that although
the entries were not available for a particular date, participants did take the
drug/placebo as scheduled. Also as the drug works slowly, missing a day
or two should not cause dramatic changes. It can also be noted that number
of missing days consecutively were 1 in most of the cases and 5 days in the
worst case.
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Figure 2.6: Variable FM symptoms (dotted line) along with its filtered through a
three day moving average version (solid line) for participant 40.
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• Prefiltering. Considering the nature of behavioral data that is collected on a
daily basis, there is a lot of variability per question, per participant as seen in
Figure 2.6. In order to decrease the variance of individual signals and remove
high frequency variations that we would like to exclude form our estimated
models, we impose a low pass filtering. Our intuition lies in emphasizing
the low frequency information content. By working with the data and as
suggested in [10], we found that the time domain method of three day moving
average worked best in terms of smoothing out the signals.
y[n] =
x[n]+ x[n−1]+ x[n−2]
3 (2.41)
The z transform representation of this prefilter is:
L(z) = (1+ z−1 + z−2)/3 = (z2 + z+1)/3z2 (2.42)
It is important to note that the moving average is applied to all the input
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Figure 2.7: Amplitude ratio plot for the three day moving average function.
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signals (including drug and placebo) to prevent any bias errors. It can be
noted in Figure 2.7 that the moving average filter will emphasis frequencies
up to 1 rad/day. This bandwidth limitation will be important later on when
performing parameter estimation.
2.7 Continuous Models and Classification of Participants
Clinical trials are conducted to scientifically test the effect of an intervention com-
ponent and notes outcomes of interest like pain and sleep. Hence after the comple-
tion of the trial, the experimenters are interested in the analysis aimed at judging
the effectiveness of the intervention. Some of the specific questions of interest are:
• Does a participant respond to the drug?
• If yes, then how fast does the drug cause a measurable effect?
• How does the response compare for different outcomes?
• How does the participant respond to placebo?
• How can the response of two different participants be compared?
The word “response” implies the interest in effect of the prime intervention compo-
nent, say drug, on primary outcomes as mentioned in the daily dairy report. In
a placebo controlled experiment, the drug response has to be stronger than the
placebo response for the drug response to be considered significant.
The procedure to generate these low-order process type models is as follows:
we use the ‘best’ estimated ARX model as the base model and calculate the step
response of these models to generate a new set of input-output data. This data is
now used to fit a continuous time model. The real input-output data could have
been used to generate continuous models directly but we use this two step approach
52
as the first ARX estimate is a consistent estimate with asymptotic theory [35] and
after having obtained such consistent estimate, a reduced parsimonious model is
obtained. The estimation of continuous models has been implemented using the
‘Process Models’ routine in MATLAB. In addition, when the gain of the drug-FM
model, for example, is positive, we can say that the FM symptoms have worsened
with introduction of drug and hence the participant did not responder to the drug
or is a non-responder. Similarly, when the drug-FM gain is negative and lets say
another model gain, of placebo-FM, is positive; this will imply that with introduc-
tion of drug, FM symptoms were decreased where as with introduction of placebo,
they increased. This would be an ideal case and the participant can be called as a
responder. In general, we classify a participant as a responder based on the gain
of drug-FM model. Similar classification can be made based on gain of drug-sleep
model whose gain has to be positive for responders implying improvement in sleep
with the intervention.
We use the classical Ist order and II order (with zero) models to represent the
dynamic characteristics of the system and their step responses are shown in Fig-
ure 2.8. The first is a classical first order system shown in differential equation
form as
τ
dy(t)
dt + y(t) = Kpu(t) (2.43)
written in transfer function form as:
Y (s)
U(s)
= G(s) =
Kp
τs+1
(2.44)
where Kp is the steady-state gain, τ is the time constant and t represents a con-
tinuous time variable. The steady-state gain value indicates how much change in
the output occurs per unit change in the input at final time; the time constant τ
provides a sense for the speed-of-response as shown in Figure 2.8a with Kp = 40,
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(b) Second order underdamped system response
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(c) Second order overdamped system response
ζ = 3.3
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Figure 2.8: Step response of low order (Ist and IInd) continuous models with label-
ing of important characteristics.
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τ = 2. The first-order model is limited in that it cannot capture oscillatory behavior
or overshoots and undershoots in the response.
The second low order model used in this procedure is a second order system
with a zero. This simple model can account for a wide array of responses including
inverse response and underdamped, critically damped and overdamped system re-
sponses. This model can be represented in second order differential equation form
as:
τ2
d2y(t)
dt2 +2ζτ
dy(t)
dt + y(t) = Kp
(
τa
du(t)
dt +u(t)
)
(2.45)
or in as a second order transfer function form as:
Y (s)
U(s)
= G(s) =
Kp(τas+1)
τ2s2 +2ζτs+1 (2.46)
where initial conditions are assumed to be zero. We can quantify the steady-state
gain (Kp) which represents magnitude of the effect, rise time (Tr; the time required
for the response to first rise from 10% to 90% of its steady state value), peak time
(Tp; time requird to reach the maximum of the curve) and settling time (Ts; the
time required for the response to reach within 98% of its steady state value) which
represents speed of the effect, from a step response of this model. These transients
are labelled for both first order and second order responses as shown in Figure 2.8
with paramters values as Kp = 40, τ = 1.57 and different ζ as mentioned in the
caption. The oscillatory nature of the response is determined by the damping factor
ζ (based on which we can classify as underdamped (0 < ζ < 1) as shown in Figure
2.8b, critically damped (ζ = 1) and overdamped (ζ > 1) as shown in Figure 2.8c. In
Figure 2.8d, we show the effect of left-half plane (LHP) zeros and right-half plane
(RHP) zeros with the inverse response noted in the case of RHP zero. These results
are tabulated for all participants in the next Chapter.
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2.8 Validation of Estimated Models
Model validation is central in judging the quality of estimation using methods in
system identification [35]. We use the following methods for model validation:
• Classical correlation analysis on residuals or residual analysis
We conduct a residual analysis on all estimated models using the auto corre-
lation on the residuals rˆe(τ) as
rˆe(τ) =
1
N
N
∑
t=1
e(t)e(t− τ) (2.47)
and cross correlation between residuals and input rˆue(τ) as
rˆue(τ) =
1
N
N
∑
t=1
u(t − τ)e(t) (2.48)
For most of the participants in this study, ARX [2 2 1] or [4 4 1] met classical
prediction error criteria where it was noted that the auto correlation of resid-
uals were white (specially when using ARX structure, they have to be white
[35]) and so were the cross correlation between the inputs and residuals. It is
also worth noting that correlation between u(t) and e(t) for negative lags can
be taken as an indication of output feedback in the input [35].
• Cross validation
Another standard test for model validation is simulating the system for a fresh
validation set and noting how much of output was explained by the estimated
model; this is called cross validation. When the data was partitioned into
estimation and validation, the estimation data was found not to have enough
excitation for multi-input estimation and hence we could not cross validate
our models. Due to limited data points in this study and due to experiment
design followed, it was not possible to maintain enough input power in the
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estimation data set. It can probably be said for typical clinical trials, follow-
ing similar protocol, that there may be a possibility that the data collected will
not allow the use of the cross validation procedure. Also, a gap between drug
and placebo administrations will reduce cross correlations between these two
variables.
• Model error model
Classical criteria such as residual analysis and cross validation do not give
any insight into model error useful for control. Another method, which is
called model error analysis [60], can give additional insight with better repre-
sentation of model error in the frequency domain. In a prediction error frame-
work, asymptotic theory can be used to generate probabilistic or ‘soft’ uncer-
tainty bounds given that there are no unmodeled dynamics [35]. A model
error model can be used as an alternative to test the model quality and any
presence of unmodeled dynamics.
As the name suggests, we fit a model to the input-output data defined as inputs
signals in the original model to the model residuals, which can be defined as:
e(t) = Ge(q)u(t)+He(q)w(t) (2.49)
where Ge is estimated using a high order ARX model (which acts as an con-
sistent estimator [35]) or an OE model and He will be the noise model for this
model error model. Ideally, the estimated model should be zero (or of very
small gain) and can be analyzed by Bode plots (with the estimated standard
deviations) of the model error model. The norms of these models can be used
in robust control techniques.
• Step responses from estimated ARX models
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After a model has passed residual analysis, we also take a look at the step
responses. Models which may not describe great deal of output variance, we
can notice a ramp type response to step input as shown in Figure 2.9, model
1. Similarly in the same figure, we show step responses of five models as
discussed before in Section 2.5.2.2. We can notice that second input onwards,
the responses tend to settle in steady state with some dynamics. In addition,
step response bounds can be constructed as shown in Figure 3.18 for example,
to give time domain information on the model uncertainty.
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Figure 2.9: ARX model step responses for the drug-FM symptoms as shown for
participant 5.
2.9 Algorithms for Input Selection
In previous sections, we discussed on how data is preprocessed, fitted to a paramet-
ric model using prediction error methods and then is approximated as a continuous
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model. We specifically emphasize how the problem at hand is about estimating
multi-input single-output (MISO) models. Hence, in addition to using standard sys-
tem identification methods we use specific techniques which deal primarily with the
choice of inputs for MISO model estimation. These methods are:
• Manual method
In this procedure, we manually add or remove inputs and experiment with
different orders and input combinations to arrive at a conclusion. We try to
answer the question: Which input combination will best describe the output
variance? The best input combination is such that a trade off between bias and
variance is achieved. There also could be a priori knowledge that enters into
choices of inputs in this approach. First, we also look for cross correlation
of those variables with output (e.g., FM sym) and if significantly correlated,
that variable can be probably classified as an output. This implies that as pain
symptoms go down, the variable under choice also changes indicating a pos-
sible output. Now, excluding these variables and forming a sub-domain of
m inputs, we can estimate multi input models. Not all inputs can be chosen
from this set; we choose those variables which we feel are good candidates
as inputs. This is tested, first, by primarily looking at any significant cross
correlation and cross spectra (such variables are not good inputs as they will
result in a biased estimate) and secondly by looking the improvement in the
model fit (if any). Each input combination will differ for each participant
and hence the model is adapted to the dynamics of each participant (and un-
derlines our approach for single subject analysis). In each estimated model,
we look at different model fits for different input combinations, their step re-
sponses and finally, we validate the model using residual analysis and other
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model validation methods.
• Step-by-Step method
In step-by-step method, we first define a criteria based on which model qual-
ity can be judged initially. For example, let us consider this criteria to be
percent fit. The algorithm then first estimates a SISO model with the input
which best described the output variance. This input is selected out of a given
n inputs by the user. After this, the algorithm estimates a two-input model
where the first input was already selected in previous step. Hence, the best
second input which describes the output variance is selected and the process
is repeated until the best model structure is found. If we use percent fit as
the criteria, there is no check for over parametrization and hence we have to
rely on user discretions for model interpretation. As an alternative, Akaike’s
Final Prediction Error (FPE) can also be used as the criteria. The final model
obtained is then validated with standard tests such as residual analysis. If the
model is not validated, the process is repeated with different input combina-
tions. For many participant cases, the step-by-step procedure converged to
the multi-input model estimated manually by the user thus validating each
other in process.
• All-combinations method
This is a brute force approach where a particular outcome is selected as output
(e.g, pain) and then the algorithm estimates all possible input combinations
(i.e., 1-input, 2-input,.., m-input) models and uses a criteria to find the best
possible model. The total number of models that have to evaluated in this
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method can be given as:
(
m
1
)
+
(
m
2
)
+ ...+
(
m
m
)
= 2m −1 (2.50)
This approach is used primarily to see if there are any other input combination
which might have been overlooked by previous two approaches. In most
of the cases, the models arrived upon by manual choices or by the step-by-
step method represent the best possible model description under given model
orders. This was confirmed with comparison of model from all-combinations
approach where it was noted that adding too many inputs resulted in an over
parametrized model which though of a higher fit is not necessarily predictive.
The results from this method have not been presented in this thesis for brevity.
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Chapter 3
ESTIMATING PARSIMONIOUS MODELS: RESULTS AND SUMMARY
3.1 Overview
In this chapter, we illustrate the system identification modeling procedure discussed
in Chapter 2. We provide a summary and tabulation of responses from all partic-
ipants, presenting one final dynamical model which best describes their response.
To further expand the modeling discussion, we rely on two representative cases:
‘Participant #5’ from the pilot study and ‘Participant #38’ from the full study. Both
of these participants are responders to drug.
To analyze the intervention, we build multi-input single-output models for each
participant where the outcomes of interest are used as outputs (e.g., pain and over-
all sleep) and drug, placebo other external factors are used as potential inputs.
For reference, we restate our modeling steps as following: (i) data preprocessing,
(ii) discrete-time parametric modeling using ARX model structure and (iii) simpli-
fication to a first and second order continuous time model . We begin with “eye-
balling” the available data and looking for changes in the time series, particularly
once the drug is introduced. We also use statistical relationships tools such as corre-
lation to extract useful information, such as any cross correlation between possible
variables of interest which could give biased estimates (as discussed in Section
2.5.2.1). In the ensuing step, we use an ARX model of order [2 2 1] and higher as
a base model structure for analysis using possible nu inputs, as chosen by the user.
In an approach to select the input combinations, we present the model estimation
method using the ‘manual method’ i.e. the model cases which are chosen manually
by looking at the input signal correlations, power spectra and then finally comparing
based on model fit and residual analysis of the estimated model. In this method, we
aim at not including ‘too’ many inputs, as overfitting will reduce predictive ability.
We also briefly explore the alternative i.e., the ‘step-by-step’ approach, as described
in Section 2.9, as an alternative where we use the percent fit as the criteria to choose
inputs.
Looking at the available variables as inputs from the daily diary report, we
can list them as (1) drug (2) placebo (3) life (4) sadness (5) anxiety (6) stress
(7) mood (8) think and remember (9) gastric symptoms (10) headaches (11) tol-
eration (12) side effects . It can be noted the variables included here are assessed
on a scale of 0−100. This leaves potentially 12 variables as inputs. Data from the
physical tests has not been used for modeling purposes. Also, adding typical ‘out-
puts’ as inputs did not yield good estimates and hence their inclusion is not seen
as beneficial. The initial model is formed with drug as input and FM symptoms as
output. In the second model, placebo is added as the second input. For the manual
method, similarly more inputs are added to the primary inputs (drug and placebo)
as they result in better goodness of fit. In case of step-by-step method, the algorithm
chooses the inputs. In all these models, FM symptoms is kept as the only output. A
similar procedure can be adopted for other outputs, and is further examined in our
analysis for the case of overall sleep variable as output.
The rest of the chapter is organized as follows. In Section 3.2, we discuss the
modeling results for Participant 5. Section 3.3 provides a summary of results for
all the participants in the pilot study. In Section 3.4, we apply the procedure, as
explained for Participant 5, to illustrate modeling results for Participant 38. In
Section 3.5, we summarize the results for all the participants in the full study and
we end with comments on the secondary data analysis for naltrexone intervention
in Section 3.6.
63
3.2 Participant 5
The original data was treated for missing entries using simple mean of immediate
neighbors and was prefiltered with a three day moving average. There were some
missing days but there were no cases where data was missing for many consecutive
days (where the method using means will fail). First, let us examine various time
series for this participant as shown in Figures 3.1-3.4. This participant is a particular
example of a typical ‘responder’ or a subject that shows a strong reaction to drug
in reducing general pain symptoms (see Figure 3.1b). In addition to the primary
outcome, we notice that overall sleep quality (Figure 3.2e), fatigue (Figure 3.1e),
gastrointestinal symptoms (Figure 3.3a) and headaches (Figure 3.3b) also improve
with drug administration.
Next, we look at possible cross correlation between variables which can be
added as inputs. As drug and placebo are used as primary inputs, we are interested
in their time lagged correlation functions with the 12 potential inputs as well as
other outputs. The cross correlation plot for drug is shown in in Figure 3.5 and for
placebo in Figure 3.6. In both figures, the horizontal band represent the bound for
statistical significance at two standard deviation i.e.  95% confidence interval.
The correlation has been shown for ±20 lags.
First, we note that drug and placebo are significantly correlated at time lags
away from zero. This is primarily due to the experimental design where there was
no ‘gap’ between the time drug was stopped and placebo was administered and
vice-versa. It can be argued that a washout period between drug and placebo would
have helped reduce the cross correlations. Since this is a secondary analysis, we
neglect this consideration and proceed with other inputs. In the case of drug, it has
almost significant cross correlation at lags for most of the variables although at lag
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Figure 3.1: Original data time series (dashed) with three day moving averaged data
(solid) for variables 1 through 6 for Participant 5. X-axis represents time (days) and
Y-axis represents the response.
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Figure 3.2: Original data time series (dashed) with three day moving averaged data
(solid) for variables 7 through 12 for Participant 5. X-axis represents time (days)
and Y-axis represents the response.
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Figure 3.3: Original data time series (dashed) with three day moving averaged data
(solid) for variables 13 through 18 for Participant 5. X-axis represents time (days)
and Y-axis represents the response.
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Figure 3.4: Original data time series (dashed) with three day moving averaged
data (solid) for variables 19,20 and the three measurements from physical tests
for Participant 5. X-axis represents time (days) and Y-axis represents the response.
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0, we do not see a very strong relation. Similarly for placebo, we see significant
correlation with most of the inputs and is more prominent than that in the case
of drug. An important inference can be made that in most of the cross correlation
scenarios, the correlation of drug with other variables is in positive or in other words
it helps in improving the symptoms where as for placebo, we see mostly correlation
is negative implying worsening of condition with introduction of placebo. As will
be noted in the discussion on model gains, the placebo response is with a positive
gain for placebo-FM model.
After evaluating the correlations associated with drug and placebo, we look at
other variables. In Figure 3.7 and 3.8, we show cross correlations between anxiety,
mood, stress, gastric and headache and note that variables gastric and headache are
cross correlated with rest of the them (i.e., anxiety, mood, stress) as well as with
the output (FM sym) (as shown in Figure 3.8) and hence excluding them may be
necessary. These cross correlations give insights into the potential bias if used as
inputs and will be used later on in the chapter.
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(h) Drug and Sadness
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(i) Drug and Side Effects
Figure 3.5: Correlation plots between drug and other variables with two standard
error bounds over ± 20 lags for Participant 5 (cont.).
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(j) Drug and Toleration
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(m) Drug and Fatigue
Figure 3.5: Correlation plots between drug and other variables with two standard
error bounds over ± 20 lags for Participant 5.
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(a) Placebo and Drug
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(b) Placebo and Anxiety
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(c) Placebo and Stress
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(d) Placebo and Mood
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(e) Placebo and Gastric
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(f) Placebo and Headache
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(h) Placebo and Sadness
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(i) Placebo and Side Effects
Figure 3.6: Correlation plots between placebo and other variables with two standard
error bounds over ± 20 lags for Participant 5 (cont.).
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(j) Placebo and Toleration
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(k) Placebo and OSleep
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(l) Placebo and Sleep
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(m) Placebo and Fatigue
Figure 3.6: Correlation plots between placebo and other variables with two standard
error bounds over ± 20 lags for Participant 5.
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(a) Anxiety and Stress
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(b) Anxiety and Mood
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(e) Stress and Mood
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(g) Stress and Headache
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(h) Mood and Gastric
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(i) Mood and Headache
Figure 3.7: Cross correlation plots between some selected variables with two stan-
dard error bounds over ± 20 lags for Participant 5.
Before moving on to estimating models, we look at the power spectra for various
variables involved in this study as shown in Figures 3.9, 3.10 and 3.11. We note that
different magnitudes for some signals is due to the different units of measurements
that are used (e.g. drug (mg), thermal pain (◦C)). From theory, we note that system
identification results in frequency band without excitation may be highly uncertain
[35]. It can be noted in Figure 3.9-3.11, the bandwidth of the available signals is
approximately 0.6 rad/day.
Upon experimenting with several input combinations, we can construct the fol-
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(a) Gastric and headache
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(b) FM sym and gastric
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(c) FM sym and headache
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(d) Life and sadness
Figure 3.8: Cross correlations between selected variables (including the output FM
sym) with two standard error bounds over ± 20 lags for Participant 5.
lowing seven models for our analysis of Participant 5:
1. Model 1 (Drug)
2. Model 2 (Drug, Placebo)
3. Model 3 (Drug, Placebo, Anxiety)
4. Model 4 (Drug, Placebo, Anxiety, Stress)
5. Model 5 (Drug, Placebo, Anxiety, Stress, Mood)
6. Model 6 (Drug, Placebo, Anxiety, Stress, Mood, Gastric)
7. Model 7 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache)
8. Model 8 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life)
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Figure 3.9: Power spectral density of all variables for Participant 5.
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Figure 3.10: Power spectral density of all variables for Participant 5.
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Figure 3.11: Power spectral density of all variables for Participant 5.
9. Model 9 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life,
Sadness)
Each of these models has FM sym variable as its output. Although we do in-
clude life and sadness as potential inputs as they are not very strongly correlated
with other variables (although it can be noted they are cross correlated among
themselves as in Figure 3.8), these variables did not cause any significant change in
model accuracy. The case of Model 5, in our opinion, works best among the choices
available as these input combinations did not seem to correspond to overparameter-
ization; this is further discussed in the following paragraphs. It is important to note
that this conclusion is only for participant 5 and cannot be generalized.
ARX [2 2 1] models were found to be adequate and hence higher model orders
were not used. When higher order models were used, the model step response was
observed to be unstable. Further adding headache and gastric (i.e. model 6 and 7)
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did not yield any significant improvements. Adding variables ‘toleration’ and ‘side
effects’ did not yield any good estimates either. Similarly life and sadness also did
not add much to the discussion. It should be mentioned here that just using drug
and placebo as inputs yields a model fit of upto 59% which suggests that drug and
placebo have a strong effect on the output and hence the model can explain a sig-
nificant amount of output variance as shown in Table 3.1. In conclusion, choosing
inputs is first initiated by looking the time series, their cross correlations and then
the final usefulness is judged by the quality of models resulting from them.
Table 3.1: Tabulation of model fits of models using FM sym as output, for partici-
pant 5.
Model % fit
1 46.5
2 59.2
3 64.7
4 71.8
5 73.9
6 71.1
7 74.4
8 74.5
9 79.6
The evolution of percent fit is shown in Figures 3.13 and 3.14 as represented
by model 1 to model 9. It can be observed that after model 5, the fit does not
improve significantly as well as do the steady state gains and hence can be see as
an increasing signs of over parametrization. The models are first validated using
the standard residual analysis [35]. Figures in 3.12, we show autocorrelation of
the residual and cross correlation of the residual with other inputs and hence the
estimated model passes the whiteness test. If the model is assumed to be in the
model class, it can be assumed ideally that model has no significant unmodeled
dynamics as well as the parametric uncertainty is reliable [60].
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An uncertainty region can be constructed as per the prediction-error framework.
Since we do not have the flexibility of input signal design, we have tried the best
combination that gives tighter bounds. The bound are show in frequency domain
as the Bode plots of estimated models along with the corresponding model error
models (as discussed in Section 2.8) in Figures 3.15-3.16. The bound is shown in
the shaded region around the nominal or mean response representing 95% confi-
dence region. The model error model is estimated using the high order ARX [880].
Althouh the model error model response is smaller in magnitude as compared to
corresponding Bode plot for the nominal model, we do not have tight bounds. The
same can be said about the bounds for the nominal model, that these are not tight.
Also, in Figure 3.17 we show the frequency magnitude plot for the estimated noise
model. It can be noted how the bounds get tighter in the higher frequency region.
Similarly, the bounds (95%) are shown in the time domain in Figure 3.18 using
the step response although we show only two cases: drug-FM model and placebo-
FM model. In all these bounds (both frequency domain and time domain), it is
important to state that although the bounds are not very tight for these estimated
models, the model has been validated by the residual analysis. Also, as these es-
timated models do not become unstable due to the uncertainty bounds, they are
more or less acceptable for the intended control application. Ultimately, the control
design goes hand-in-hand with modeling and hence the control system has to be
designed robust enough for plant-model mismatch.
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Figure 3.12: Classical correlation analysis test on residuals (with 99% confidence
intervals) using 7 inputs (or model 7) for Participant 5. Similarly model 5 meets the
requirements for residual analysis.
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Figure 3.13: Estimated model (1-5) output vs. actual (FM sym) output using ARX
[2 2 1] for Participant 5.
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(a) Model 6
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(b) Model 7
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Figure 3.14: Estimated model (6-9) output vs. actual (FM sym) output using ARX
[2 2 1] for Participant 5.
83
Am
pl
itu
de
From u1 to e@y1
10−3 10−2 10−1 100 101
10−1
100
101
Ph
as
e 
(de
gre
es
)
Frequency (rad/s)
10−3 10−2 10−1 100 101
−400
−200
0
200
(a) Drug to e
Am
pl
itu
de
From u1 to y1
10−2 10−1 100 101
10−1
100
101
Ph
as
e 
(de
gre
es
)
Frequency (rad/s)
10−2 10−1 100 101
0
50
100
150
200
(b) Drug to FM
Am
pl
itu
de
From u2 to e@y1
10−3 10−2 10−1 100 101
100
101
102
103
Ph
as
e 
(de
gre
es
)
Frequency (rad/s)
10−3 10−2 10−1 100 101
−400
−200
0
200
(c) Placebo to e
Am
pl
itu
de
From u2 to y1
10−2 10−1 100 101
101
102
Ph
as
e 
(de
gre
es
)
Frequency (rad/s)
10−2 10−1 100 101
−200
−150
−100
−50
0
(d) Placebo to FM
Am
pl
itu
de
From u3 to e@y1
10−3 10−2 10−1 100 101
10−2
10−1
100
101
Ph
as
e 
(de
gre
es
)
Frequency (rad/s)
10−3 10−2 10−1 100 101
−400
−200
0
200
(e) Anxiety to e
Am
pl
itu
de
From u3 to y1
10−2 10−1 100 101
10−2
10−1
100
Ph
as
e 
(de
gre
es
)
Frequency (rad/s)
10−2 10−1 100 101
−200
−150
−100
−50
0
(f) Anxiety to FM
Figure 3.15: Bode plots for the model error model and nominal model (with 95%
confidence interval) of estimated ARX model using model 5, for participant 5.
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Figure 3.16: Bode plots for the model error model and nominal model (with 95%
confidence interval) of estimated ARX model using model 5, for participant 5.
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Figure 3.17: Frequency magnitude plot (with 95% confidence intervals) of noise
model for Participant 5.
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Figure 3.18: Step responses with 95% confidence intervals (marked by ‘+’) of
model 5 of drug-FM and placebo-FM pairs for Participant 5.
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Coming to last step (iii) of system identification procedure, we now present a
tabulation of models and step responses. From Figure 3.19 onwards, we show the
step responses of estimated ARX model where FM sym is chosen as the output.
In each figure, an input is taken from the multiple inputs in the model, and the
change in output is seen for a step change in that chosen input. Each figure is
also accompanied with tabulation of first and second order continuous time model
approximations. It can be restated here that since we estimate five input models,
the first input-output pair (namely, drug-FM) is present in five models (i.e. model 1
to model 5), the second input-output pair is present in four models and so on.
The model parameters for each case of step response have been tabulated in Ta-
bles 3.2-3.7. Looking at the tabulations for respective step response, we note that
the participant responds to the drug with final gain for drug-FM model being neg-
ative (implying decrease in pain and this was expected from the time series trends
as shown in Figure 3.1b) and the final gain for placebo-FM model is positive (im-
plying worsening of pain). The evolution of the gain and other dynamical system
characteristics can also be noted in the tabulations. In Figure 3.24, we show a drug-
Overall Sleep model to analyze the effect of drug on sleep. Here we note that the
final gain is positive, implying that the administration of drug has resulted in an
improvement in sleep.
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Figure 3.19: Step response of drug-FM model for Participant 5.
Table 3.2: Step response tabulation of drug-FM model for Participant 5.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
1 46.57 -11.82, 4.25 -12.03, 5.67, 4.14, 21.3 75.5 139.69
2 59.26 -1.03, 0.001 -0.91, 3.5, 2.67, 44.4 0.43 75.06
3 64.78 -1.07, 0.001 -1.02, 2.09, 1.5, 15.3 0.43 25.68
4 71.89 -3.11, 3.79 -3.11, 1.62, 1.24, 0.22 7.53 14.38
5 73.99 -2.46, 1.84 -2.47, 1.57, 1.26, 1.96 5.12 11.49
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Figure 3.20: Step response of placebo-FM model for Participant 5.
Table 3.3: Step response tabulation of placebo-FM model for Participant 5.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
2 59.26 73.66, 13.71 74.07, 3.5, 2.67, 7.17 32.81 63.18
3 64.78 61.87, 4.89 61.92, 2.09, 1.5, 1.46 11.48 21.79
4 71.89 44.25, 2.09 44.3, 1.62, 1.24, 1.79 5.56 11.96
5 73.99 45.79, 2.78 45.81, 1.57, 1.26, 1.15 6.59 13.06
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Figure 3.21: Step response of anxiety-FM model for Participant 5.
Table 3.4: Step response tabulation of anxiety-FM model for Participant 5.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
3 64.78 1.42, 5.34 1.42, 2.09, 1.5, 1.04 11.97 21.39
4 71.89 0.66, 3.49 0.66, 1.62, 1.24, 0.54 7.34 13.98
5 73.99 0.87, 3.72 0.86, 1.57, 1.26, 0.24 7.45 14.24
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Figure 3.22: Step response of stress-FM model for Participant 5.
Table 3.5: Step response tabulation of stress-FM model for Participant 5.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
4 71.89 2.05, 3.41 2.05, 1.62, 1.24, 0.63 7.28 13.89
5 73.99 2.29, 3.49 2.29, 1.57, 1.26, 0.49 7.31 13.94
92
0 10 20 30 40 50 60 70
−0.12
−0.1
−0.08
−0.06
−0.04
−0.02
0
Subject ID
5
Input:
Mod
Output:
FMsm
Number of Days
O
ut
pu
t R
es
po
ns
e
 
 
model5%73.9943
Figure 3.23: Step response of mood-FM model for Participant 5.
Table 3.6: Step response tabulation of mood-FM model for Participant 5.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
5 73.99 -0.092, 0.18 -0.091, 1.57, 1.26, 4.67 0.8 11.93
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Figure 3.24: Step response of drug-overall sleep model for Participant 5.
Table 3.7: Step response tabulation of drug-overall sleep model for Participant 5.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
1 5.80 19.23, 19.04 19.14, 4.1, 2.18, -4.27 37.21 69.88
2 33.74 18.35, 16.78 18.25, 3.72, 2.04, -5.27 31.3 59.41
3 32.28 16.17, 14.6 16.08, 3.42, 1.86, -5.63 25.86 49.76
4 38.18 8.86, 10.66 8.82, 2.86, 1.64, -3.17 18.52 36.22
5 42.61 5, 6.36 4.98, 2.13, 1.04, -3.35 7.06 15.83
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So far we have discussed the procedure which we refer to as the manual method.
Similarly, we now briefly mention the results from the step by step procedure.
When give nine inputs as drug, placebo, anxiety, stress, mood, gastric, headache,
life and sadness, the algorithm chooses the input combination as follows based on
the improvement in model fit in the following order of inputs: placebo, headache,
anxiety, sadness, stress, drug, mood and gastric.
It is interesting to note that in the step-by-step procedure, drug was chosen
as the sixth input. As the algorithm uses the model fit as the criteria to choose
inputs, we cannot conclusively comment on this result as to why drug was chosen
so later. Overall, we can say that most of the result from both the manual approach
and the step-by-step approach converge to more or less similar choice of inputs
for participant 5. Hence, detailed modeling results are not shown for step-by-step
approach due to similar conclusions.
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3.3 Summary for Pilot Study
There were a total of 10 participants in the pilot study which included participant
5. From analysis of the results, we note that participant 5 is one of the stronger
responders to the drug. In this work, we try to use a common model structure
(ARX) as well as common input combinations (as in model 5) to compare all the
results from different participants as it worked more or less for all cases but for
some cases e.g. for participant 9, different input combinations are examined. The
model order used was ARX [2 2 1] unless otherwise noted. We observed that it was
necessary to go beyond the primary inputs (drug and placebo), in order to improve
model fits to the diary data. However, simply adding inputs does not necessary
result in models with predictive ability. Hence we tried to systematically arrive at
the most useful and interesting input-output combinations, which resulted in the five
or more input combinations as noted. Figures 3.25, 3.26 shows the percentage fits
using model 5 (drug, placebo, anxiety, stress, mood) for all participants. Here we
observe that the best fit was obtained for participant #5 and the worst for participant
#6. It can be noted that most of the poor fits were observed for cases which did not
react to the intervention or in other words, the time series was more or less flat. All
tabulations refer to Tables 3.8 and 3.9.
In [10], participants # 5, 7, 9, 10, 11 and 12 are classified as responders and par-
ticipants # 3, 6, 8 and 14 are classified as non-responders. The basis of classification
used is that the responders are subjects who show a 30 point reduction of symptoms
over placebo. Based on our analysis on the Drug-FM symptoms response curve, we
classify the subjects as ‘responders’ if the response gain or the nominal gain is neg-
ative and ‘non-responders’ if the gain is not negative. As noted previously, negative
gain implies that drug lowers FM symptoms and hence for ‘responders’, we expect
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gain to be negative. Under this classification, Subjects # 5, 7, 9, 10, 11, 8 and 14
classify as responders (seven participants) and # 12, 3, 6 (three participants) as non
responders in our analysis. When compared to [10], we notice that participant # 12,
who is classified as a responder, is a non-responder in our analysis and participants
# 8 and # 14, who are classified as non-responders, are responders. Although it has
to be noted there are borderline cases on both responder and non-responder sides,
including # 12, as we classify based on the nominal gain of estimated models and
hence on incorporating the standard deviation, from the prediction error method,
a range can be established in which a participant can be both a responder and a
non-responder.
Our a priori assumption is that naltrexone lowers FM symptoms and hence
we expected that the drug-FM response should reflect a negative gain. Because
the magnitude and speed of this change can vary significantly among participants,
we show a single-subject analysis. All participants were analyzed in detail, but
for the sake of brevity, we have presented, in detail, both step response plots and
corresponding dynamical system tabulations only for Participant 5 (as discussed
before). For all participants, we tabulate responses using one final model for drug-
FM, placebo-FM, drug-overall sleep and placebo-overall sleep cases as shown in
Tables 3.8 and 3.9.
Another point to note is the response to placebo as input. All participants (ex-
cept # 7, #8, #10 and #14) show a positive gain for Placebo-FM symptoms response
implying increase in symptoms with Placebo intake. For sleep as an output, all par-
ticipants show positive gain for drug intake except #7, #6 and #11. Researchers
working on FM are interested in finding an answer to the question of the rela-
tionship between sleep and pain among the various participants. To this end, we
conducted our analysis using sleep as the output in lieu of FM symptoms. Here our
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hypothesis was that comparing the speed-of-response/settling time from the drug
response for these two outputs would give us some insights into this issue. For re-
sponders, based on averaged response we observe that the drug-sleep response is
faster than the drug-FM response (i.e., the drug-sleep response displays a shorter
settling time) as noted in Table 3.8 although such a relationship is not conclusive
and is not prominent across all participants.
Some of our particular findings from the secondary analysis are as follows:
• The set of inputs which seem to be appropriate for all participants were: drug,
placebo, anxiety, stress, mood, gastric and headache i.e. model 7 however
model 5 was found to be a better alternative. Specific ARX models formed
from this set of inputs are mentioned in Section 3.2. The goodness of fit ob-
tained from the estimated ARX models (using FM as output) ranged from
73.99% (for participant #5) to 16.98% (for participant #6) as shown in Fig-
ures 3.25,3.26. Similarly, the goodness of fit obtained from the estimated
ARX models (using Overall sleep as output) ranged from 42.61% (for partic-
ipant #5) to 11.6% (for participant #8) as shown in Figures 3.27,3.28.
• The participants are re-classified [10] as responders and non-responders based
on the value of the nominal gain of the drug-FM symptoms model. For re-
sponders, the drug-FM response has negative gain while for non-responders
the drug-FM response shows a positive gain. Based on this criteria, we clas-
sify participants # 5, 7, 9, 10, 11, 8 and 14 as responders and # 12, 3, 6 as
non-responders. Goodness of fit varied from 18.85% to 73.99% for respon-
ders and from 16.98% to 23.92% for non-responders, as noted in Table 3.8.
• How strongly participants responded to naltrexone is quantified by the gain
of the drug-FM response. It was noted that participant #9 showed the largest
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gain and participant # 14 showed the least gain for responders; the gain of
drug-FM response ranged from -2.31 (for participant #7) to -11.08 (for par-
ticipant #9), as summarized in Table 3.8.
• The settling time for participants classified as responders ranges from 8.3
days to 50.9 days and 9.5 days to 11.9 days for non-responders. The fastest
settling time was observed from participant #9 and the slowest from partici-
pant #11, as noted in Table 3.8.
• The effect of placebo on fibromyalgia symptoms was also examined. Par-
ticipants #7, 8, 10 and 14 show a negative gain for placebo-FM response,
(implying a decrease in pain with placebo) whereas for the remaining partic-
ipants all reported increases in pain with placebo (positive gain). The fastest
response to placebo was observed for participant #7, while the slowest re-
sponse was for participant #11, as noted in Table 3.9.
• A comparison of responders and non-responders when the outcome consid-
ered is overall sleep rather than fibromyalgia symptoms was considered. We
note that only participants #7 and #11 showed a negative gain for drug-sleep
response, implying a worsening of sleep quality as drug is introduced. The
remaining participants showed a clear positive gain implying improvement
in sleep quality with drug intake. All the participants classified as non-
responders, except #6, show improvement in sleep quality with drug intake.
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(a) Participant #5 (73.99%)
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(c) Participant #9 (55.74%)
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(d) Participant #10 (34.01%)
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(e) Participant #11 (56.25%)
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Figure 3.25: Estimated model output vs. actual output (FM sym), using an ARX
[2 2 1] structure per model 5 (unless otherwise mentioned) for the participants of
pilot study. Model fits are mentioned in parenthesis.
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(a) Participant #12 (23.92%)
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(b) Participant #6 (16.98%)
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(c) Participant #8 (25%)
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Figure 3.26: Estimated model output vs. actual output (FM sym), using an ARX
[2 2 1] structure per model 5 (unless otherwise mentioned) for the participants of
pilot study. Model fits are mentioned in parenthesis.
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(a) Participant #5 (42.61%)
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(b) Participant #7 (16.93%)
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(c) Participant #9 (27.72%)
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(d) Participant #10 (26.93%)
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(e) Participant #11 (30.08%)
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Figure 3.27: Estimated model output vs. actual output (overall sleep), using an
ARX [221] structure per model 5 (unless otherwise mentioned) for the participants
of pilot study. Model fits are mentioned in parenthesis.
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(a) Participant #12 (37.15%)
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(b) Participant #6 (39.75%)
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(c) Participant #8 (11.66%)
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Figure 3.28: Estimated model output vs. actual output (overall sleep), using an
ARX [221] structure per model 5 (unless otherwise mentioned) for the participants
of pilot study. Model fits are mentioned in parenthesis.
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Legend
• The system responses are grouped into four cases: DFM or Drug FM response, DS
or Drug overall sleep response, PFM or Placebo FM response and PS or Placebo
overall sleep response
• Kp(DFM/DS) is the gain (units of change in outcome per unit dose of LDN) and
Ts(.) is the settling time (in days) of system response,
• ESR (Erythrocyte Sedimentation Rate) values for each participant
• Goodness of fit of estimated models is shown by % fit
• “Average values” are the mean of data in respective columns
• ω : Using ARX [441] on model 5 input combinations
• γ : ARX [221] using inputs : Drug, Placebo, Anxiety, Stress, Mood and Life
• κ : ARX [221] using inputs : Drug, Placebo, Gastric, Headache, Life and Sadness
• The standard deviation (σ ) on data is shown by ±. Please note that σ values in
rows corresponding to each participant is the variability on estimated gains (from
system identification) where as σ values in rows corresponding to average values is
the deviation of mean of each participant’s response
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3.4 Participant 38
The data analysis from the pilot study had shown promise for the use of naltrex-
one for FM treatment and hence a full study was under taken by Younger et al. to
investigate the drug intervention under stricter experimental conditions and longer
duration. The modeling procedure is similar to that shown for the pilot study. First,
the data was preprocessed for missing days and the data trends are shown in Fig-
ures 3.29-3.32. When compared to participant 5, we do not see a very strong re-
sponse to drug although this participant had one of the strongest responses in the
full study. It should be noted that this participant follows as Placebo-Drug protocol,
similar to participant 5. In particular, we do not see any improvement in the sleep
quality with drug intervention. The data was also prefiltered with three day moving
average. Also, this data has significant variations or high frequency content as com-
pared to Participant 5, whose response were smoother. It can be commented that
since the data is obtained from self-reports, the way of reporting and the quality of
data can vary significantly between participants.
Next, we look at the cross correlation of drug and placebo with other variables.
It is shown in Figures 3.33 and 3.34, respectively. The data is correlated with drug
above significant levels for some cases like mood, anxiety and side effects. In
contrast with Participant 5, we see almost no correlation between drug and overall
sleep which was present in the first case (and hints at no effect of drug on sleep
quality). Also drug seems to make causing side effects (Figure 3.33i) and similar
inference can be made for placebo where the correlations seems to be stronger. In
Figure 3.35, we show cross correlation between other selected variables. It can
be noted that variables gastric and headache are not correlated with themselves
and with the output and hence may merit their inclusion as inputs. The placebo
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seems to make the response worse and drug makes them better, in line with what
was observed with Participant 5, but the relations are not distinct e.g., some of
the variables used in previous case study seem to more correlated in this case like
anxiety, stress, life and sadness.
The power spectra for inputs has been shown in Figures 3.36, 3.37 and 3.38.
Since this is longer protocol, we see an increase in power for some signals (e.g.,
drug) and the bandwidth is near 0.4 rad/day.
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Figure 3.29: Original data time series (dashed) with three day moving averaged
data (solid) for variables 1 through 6 for Participant 38.
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Figure 3.30: Original data time series (dashed) with three day moving averaged
data (solid) for variables 7 through 12 for Participant 38.
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Figure 3.31: Original data time series (dashed) with three day moving averaged
data (solid) for variables 13 through 18 for Participant 38.
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Figure 3.32: Original data time series (dashed) with three day moving averaged
data (solid) for variables 19,20 and three measuremenst from the physical tests for
Participant 38.
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Figure 3.33: Correlation Plots between drug and other variables with two standard
errors over ± 20 lags for Participant 38 (cont.).
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Figure 3.33: Correlation Plots between drug and other variables with two standard
errors over ± 20 lags for Participant 38.
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(e) Placebo and Gastric
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Figure 3.34: Correlation Plots between placebo and other variables with two stan-
dard errors over ± 20 lags for Participant 38 (cont.).
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(j) Placebo and Toleration
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(k) Placebo and Overall Sleep
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Figure 3.34: Correlation Plots between placebo and other variables with two stan-
dard errors over ± 20 lags for Participant 38.
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Figure 3.35: Cross correlations between various variables with two standard errors
over ± 20 lags for Participant 38.
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Figure 3.36: Power spectral density for all variables for Participant 38.
118
10−2 10−1 100 101
100
101
102
103
104
105
 
 
Anxiety
Stress
Mood
Sleep
Overall sleep
Think and rem
(a) Variable 7 through 12
10−2 10−1 100 101
10−4
10−2
100
102
104
106
 
 Gastric
Headache
Toleration
Side effects
Capsule
Capsule (last night)
(b) Variable 13 through 18
Figure 3.37: Power spectral density for all variables for Participant 38.
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Figure 3.38: Power spectral density for all variables for Participant 38.
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With manual experiments based on the possible input cross correlation, we can
construct the following models:
Model 1 (Drug)
Model 2 (Drug, Placebo)
Model 3 (Drug, Placebo, Anxiety)
Model 4 (Drug, Placebo, Anxiety, Stress)
Model 5 (Drug, Placebo, Anxiety, Stress, Mood)
Model 6 (Drug, Placebo, Anxiety, Stress, Mood, Gastric)
Model 7 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache)
Model 8 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life)
Model 9 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life, Sad-
ness)
Model 10 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life, Sad-
ness, OverallSleep)
Model 11 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life, Sad-
ness, OverallSleep, Sleep)
Model 12 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life, Sad-
ness, OverallSleep, Sleep, Fatigue)
Model 13 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life, Sad-
ness, OverallSleep, Sleep, Fatigue, Toleration)
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Model 14 (Drug, Placebo, Anxiety, Stress, Mood, Gastric, Headache, Life, Sad-
ness, OverallSleep, Sleep, Fatigue, , Toleration, Side Effects)
It can be noted that some variables like sleep, which are classified as an output,
has been used from model 10 onwards primarily in an attempt to improve the model
fit (although that does not always work). Since headache and gastric are not very
correlated as shown in Figure 3.35i, we included them in our analysis (model 6 and
7). Similarly we also include life and sadness as inputs which give good estimates
(model 8 and model 9) for many participants. We do not pursue anything above
model 9 as it was not fruitful.
The model were estimated using ARX [4 4 1] structure. When comparing with
participant 5, we note that more inputs (and higher model orders) are required to get
improvements in model fits. The correlation analysis on the residuals is shown in
Figure 3.39. Also, on using drug and placebo as the only inputs yielded a model fit
up to 39%, as noted in Table 3.10, which is not as good as the first case (participant
5) suggesting a not very strong respnse to drug. A higher model order provided a
better description of output variance. The step responses are, of course, not smooth
as compared with ARX [2 2 1] modeling.
The evolution of model fits is shown in Figures 3.40 and 3.41. The improve-
ment in model fit is not gradual as well. Similar to previous analysis of participant
5, we show the Bode plots of the model error model and nominal model as shown
in Figures 3.42-3.44. The model error was constructed using an ARX [880] model.
Since the data did not seem to suggest a strong response to drug, we do not observe
tight bounds for the estimated models. To get a sense of bounds in the time domain,
we generate step responses with 95% confidence intervals, for model drug-FM and
placebo-FM, as shown in Figure 3.46. In line with inference drawn in the case with
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Table 3.10: Tabulation of model fits of models using FM sym as output for partici-
pant 38.
Model % fit
1 38.8
2 39.6
3 41.2
4 40.4
5 43.3
6 47.9
7 48.0
8 52.8
9 54.7
models for participant 5, the wide uncertanity bounds do not cause system insta-
bility and usefulness of such models depends on the intended control application.
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Figure 3.39: Classical correlation analysis test on residuals (with 99% confidence
intervals) using model 9 for Participant 38.
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Figure 3.40: Estimated model (1-6) output vs. actual (FM sym) output using ARX
[4 4 1] for Participant 38.
125
20 40 60 80 100 120 140
20
30
40
50
60
70
y1. (sim)
y1
 
 
model7%48.0482
(a) Model 7
20 40 60 80 100 120 140
20
30
40
50
60
70
y1. (sim)
y1
 
 
model8%52.7556
(b) Model 8
20 40 60 80 100 120 140
20
30
40
50
60
70
y1. (sim)
y1
 
 
model9%54.6979
(c) Model 9
Figure 3.41: Estimated model (6-9) output vs. actual (FM sym) output using ARX
[4 4 1] for Participant 38.
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Figure 3.42: Bode plots for the model error model and nominal model (with 95%
confidence interval) of estimated ARX model using model 9, for participant 38.
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Figure 3.43: Bode plots for the model error model and nominal model (with 95%
confidence interval) of estimated ARX model using model 9, for participant 38.
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Figure 3.44: Bode plots for the model error model and nominal model (with 95%
confidence interval) of estimated ARX model using model 9, for participant 38.
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Figure 3.45: Frequency magnitude plot (with 95% confidence intervals) of noise
model of model 9, for Participant 38.
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Figure 3.46: Step responses with 95% confidence intervals (marked by ‘+’) of
model 9 of drug-FM and placebo-FM pairs for Participant 38.
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As a part of final process, step responses and tabulations of individual inputs
from model 9 estimated using an ARX [4 4 1] model structure are shown in Figures
3.47-3.56. For case of drug-FM model, it can be observed how adding extra inputs
causes the change in direction of model gain as noted in Table 3.11 (model 3 to
model 4).
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Figure 3.47: Step response of drug-FM model for Participant 38.
Table 3.11: Step response tabulation of drug-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
1 38.88 4.39 , 70.14 4.28 , 3.63 , 8.75 , -22.64 112.40 175.81
2 39.63 5.02 , 40.78 5 , 24.36 , 1.12 , 103.28 92.88 136.69
3 41.23 0.89 , 0.00 1.03 , 0.84 , 4.13 , -11.58 36.50 41.39
4 40.40 -0.24 , 17.50 -0.26 , 0.00 , 68.40 , 2517.15 0.06 34.32
5 43.36 -2.74 , 9.94 -2.73 , 5.18 , 0.97 , -12.03 0.69 34.64
6 47.92 -3.26 , 11.29 -3.24 , 5.86 , 0.96 , 0.59 0.86 34.24
7 48.05 -2.78 , 9.57 -2.76 , 5.51 , 0.90 , 0.92 0.76 28.42
8 52.76 -2.16 , 6.52 -2.15 , 4.08 , 0.89 , -7.04 0.55 23.56
9 54.70 -2.79 , 6.23 -2.79, 3.73 , 1.03 , 1.63 13.37 23.11
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Figure 3.48: Step response of placebo-FM model for Participant 38.
Table 3.12: Step response tabulation of placebo-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
2 39.63 23.54 , 30.88 23.90 , 22.76 , 1.24 , -43.49 71.83 122.36
3 41.23 12.87 , 1.91 12.86 , 0.00 , 96.53 , -55.94 0.47 16.19
4 40.40 16.00 , 6.09 16.21 , 6.16 , 1.57 , 12.96 0.51 41.90
5 43.36 11.65 , 1.44 11.65 , 0.87 , 0.34 , -1.34 0.43 19.82
6 47.92 15.79 , 1.38 15.78 , 0.80 , 0.39 , -1.06 0.51 15.03
7 48.05 16.92 , 1.23 16.92 , 0.32 , 0.65 , -3.41 0.49 13.65
8 52.76 16.23 , 1.21 16.23 , 0.31 , 0.59 , -4.03 0.50 11.05
9 54.70 7.56 , 0.65 7.49 , 1.72 , 0.51 , 3.03 1.16 21.02
134
0 10 20 30 40 50 60 70
−3
−2
−1
0
1
2
3
Subject ID
38
Input:
Anx
Output:
FMsm
Number of Days
O
ut
pu
t R
es
po
ns
e
 
 
model3%41.2282
model4%40.4043
model5%43.3641
model6%47.916
model7%48.0482
model8%52.7556
model9%54.6979
Figure 3.49: Step response of anxiety-FM model for Participant 38.
Table 3.13: Step response tabulation of anxiety-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
3 41.23 2.14 , 14.42 -7.09 , NaN , 1931.40 , NaN 28.66 53.81
4 40.40 -1.90 , 14.31 -1.90 , 22.33 , 1.09 , 0.43 31.44 56.92
5 43.36 -1.69 , 8.55 -1.69 , 7.73 , 1.01 , 7.01 18.48 34.30
6 47.92 -2.48 , 8.59 -2.48 , 5.71 , 1.06 , 3.56 18.08 33.56
7 48.05 -2.19 , 7.24 -2.19 , 3.76 , 1.16 , 1.59 14.73 27.79
8 52.76 -1.88 , 6.38 -1.88 , 1.94 , 1.71 , 0.39 13.15 25.12
9 54.70 -2.04 , 6.57 -2.04 , 1.29 , 2.45 , -0.26 13.35 25.28
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Figure 3.50: Step response of stress-FM model for Participant 38.
Table 3.14: Step response tabulation of stress-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
4 40.40 2.85 , 15.20 2.85 , 4.80 , 1.66 , 0.24 31.61 59.04
5 43.36 1.57 , 9.58 1.57 , 3.97 , 1.26 , 0.09 19.50 35.71
6 47.92 2.15 , 9.21 2.15 , 3.72 , 1.30 , 0.12 18.75 34.57
7 48.05 1.95 , 7.89 1.95 , 3.50 , 1.17 , 0.03 15.49 28.77
8 52.76 1.74 , 7.16 1.74 , 3.33 , 1.14 , 0.25 14.06 26.15
9 54.70 1.78 , 7.15 1.77 , 3.26 , 1.14 , 0.11 13.93 25.94
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Figure 3.51: Step response of mood-FM model for Participant 38.
Table 3.15: Step response tabulation of mood-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
5 43.36 0.31 , 3.33 0.32 , 1.22 , 4.41 , 6.37 14.80 29.56
6 47.92 0.45 , 6.82 0.45 , 1.14 , 3.83 , 3.10 16.32 30.77
7 48.05 0.38 , 5.51 0.38 , 1.03 , 3.62 , 2.96 13.63 25.45
8 52.76 0.78 , 3.52 0.78 , 2.91 , 1.39 , 4.04 10.56 21.84
9 54.70 0.92 , 1.05 0.91 , 1.13 , 0.54 , 0.42 2.15 9.73
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Figure 3.52: Step response of gastric-FM model for Participant 38.
Table 3.16: Step response tabulation of gastric-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
6 47.92 -0.87 , 8.40 -0.87 , 2.05 , 2.08 , 0.18 17.97 33.50
7 48.05 -0.78 , 6.95 -0.78 , 1.40 , 2.41 , -0.15 14.59 27.62
8 52.76 -0.49 , 6.32 -0.49 , 4.61 , 1.03 , 3.21 13.27 25.05
9 54.70 -0.68 , 6.96 -0.68 , 3.58 , 1.09 , 0.71 14.06 25.43
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Figure 3.53: Step response of headache-FM model for Participant 38.
Table 3.17: Step response tabulation of headache-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
7 48.05 0.09 , 10.72 0.09 , 4.09 , 0.98 , -4.81 14.37 29.90
8 52.76 0.14 , 9.41 0.14 , 3.55 , 1.02 , -3.86 12.77 27.13
9 54.70 0.13 , 7.61 0.13 , 2.75 , 1.25 , -1.41 12.59 26.42
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Figure 3.54: Step response of life-FM model for Participant 38.
Table 3.18: Step response tabulation of life-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
8 52.76 -0.50 , 1.85 -0.50 , 1.13 , 0.74 , -0.02 2.55 11.82
9 54.70 -0.62 , 2.67 -0.62 , 0.66 , 1.94 , 0.01 8.86 19.62
140
0 10 20 30 40 50 60 70
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Subject ID
38
Input:
Sad
Output:
FMsm
Number of Days
O
ut
pu
t R
es
po
ns
e
 
 
model9%54.6979
Figure 3.55: Step response of sadness-FM model for Participant 38.
Table 3.19: Step response tabulation of sadness-FM model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
9 54.70 0.75 , 1.50 0.75 , 1.24 , 0.57 , 0.18 2.50 10.49
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Figure 3.56: Step response of drug-overall sleep model for Participant 38.
Table 3.20: Step response tabulation of drug-overall sleep model for Participant 38.
Model %fit Kp, τ Kp, τ,ζ ,τa Tr Ts
1 -34.48 NaN , NaN -1.09, 0.43 , 0.48 , 3.10 0.53 189.02
2 -25.98 -2.62 , 757.46 -0.29 , 0.33 , 0.28 , 19.30 0.25 164.05
3 4.85 0.75 , 0.70 0.76 , 0.39 , 0.35 , -4.88 0.10 34.42
4 8.22 0.15 , 0.66 0.16 , 0.38 , 0.32 , -22.03 0.01 39.54
5 12.97 -2.28 , 9.54 2.18 , NaN , 1214.93 , NaN 17.93 21.88
6 13.65 -2.07 , 9.32 -2.04 , 2.44 , 0.97 , -9.45 17.79 20.97
7 15.83 -0.41 , 10.82 -0.31 , 0.39 , 0.26 , 8.07 0.23 18.56
8 17.81 0.36 , 0.61 0.36 , 0.39 , 0.27 , -8.10 0.05 11.72
9 17.93 0.39 , 0.71 0.4 , 0.38 , 0.30 , -7.41 0.07 11.57
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3.5 Summary for Full Study
There were a total of 30 participants in the full study. Overall, the response of
participants to naltrexone was not as strong when compared with cases in the pilot
study. The following inferences make use of data tabulated in Tables 3.21-3.24.
Some of our findings from secondary analysis on the full study data are as follows:
• The goodness of fit is determined by the percent variance in the output vari-
able described by the ARX model for a given model structure. In the full
study, this varies from 2.19 % (Participant # 29) to 66.41 % (Participant # 48)
for FM symptoms (as noted in Figures 3.57-3.60) and from 17.93 % (Partic-
ipant # 38) to 72.5 % (Participant # 17) for Overall Sleep.
• The strength of response to drug on FM symptoms is noted by the gain of
the drug-FM model. The gain varies from -11.66 (Participant # 33) to 4.09
(Participant # 29) for participants subjected to the Placebo-Drug protocol.
Similarly, the gain varies from -7.23 (Participant # 34) to 2.17 (Participant #
37) for the Drug-Placebo protocol.
• The strength of response to drug on overall sleep is noted by the gain of the
drug-overall sleep model. The gain varies from 6.23 (Participant # 46) to
-4.89 (Participant # 35) for participants in the Placebo-Drug protocol. Sim-
ilarly, the gain varies from 9.7 (Participant # 18) to -4.08 (Participant # 27)
for the Drug-Placebo protocol.
• The settling time for most the participants responding to drug for both output
cases (FM symptoms and overall sleep) was under 30 days on average.
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• The strength of response to placebo on FM symptoms is noted by the gain
of the placebo-FM model. The gain varies from -67.83 (Participant # 42)
to 41.48 (Participant # 17) for participants with the Placebo-Drug protocol.
Similarly, the gain varies from -61.62 (Participant # 18) to 72.44 (Participant
# 48) for Drug-Placebo protocol.
• The strength of response to placebo on overall sleep is noted by the gain of
the placebo-overall sleep model. The gain varies from 37.37 (Participant #
46) to -30.87 (Participant # 35) for Placebo-Drug protocol. Similarly, the
gain varies from 102.52 (Participant # 18) to -15.13 (Participant # 45) for
Drug-Placebo protocol.
• Based on the estimated gains for the drug-FM model, we classify the follow-
ing participants as responders : # 16, 17, 18, 19, 22, 28, 30, 32, 33, 34, 35,
38, 39, 40, 42, 45, 50 and 52 (total 18) and the remainder as non responders.
Similarly, based on the estimated gains for the drug-overall sleep model, we
classify the following participants as responders : # 16, 18, 19, 28, 30, 33,
34, 37, 38, 43, 44, 45, 46, 47, 48, 50, and 52 (total 17) and the other partici-
pants as responders. Consider the gains for both outputs (FM symptoms and
overall sleep) we have following common responders : #16, 18, 19, 28, 30,
33, 34, 38, 45, 50 and 52 (total 11).
• Placebo effects on FM symptoms are substantial in this study. It was observed
that a much greater percentage of participants display a negative gain for
drug-FM model (indicating beneficial effects of placebo) than were observed
in the pilot study. Of the 11 common responders (displaying beneficial effects
to both FM symptoms and overall sleep from drug), eight display a beneficial
effect from placebo. The magnitude of the average effect (as reflected by the
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nominal gain values) is similar to that obtained from the drug. It seems to
indicate that most participants who respond to drug respond similarly as well
to placebo and there seems to be no benefit from naltrexone treatment under
these circumstances.
• We tabulate the standard deviations of the estimated gain estimates for each
participant. It was observed that for most the participants (including many
responders), the estimated gain interval crosses over the zero gain threshold.
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(b) Participant # 17 (64.29%)
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(c) Participant # 18 (36.41%)
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(d) Participant # 19 (48.71%)
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(e) Participant # 22 (39.68%)
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(f) Participant # 25 (44.68%)
Figure 3.57: Estimated model output vs. actual output (FM sym), using an ARX
[4 4 1] structure per model 9 (unless otherwise mentioned) for the participants of
full study. Model fits are mentioned in parenthesis.
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(a) Participant # 27 (45.94%)
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(b) Participant # 28 (49.6%)
20 40 60 80 100 120 140 160
5
10
15
20
25
30
35
40
45
50
y1. (sim)
y1
 
 
model8%2.1974
(c) Participant # 29 (2.19%)
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(d) Participant # 30 (44%)
20 40 60 80 100
15
20
25
30
35
40
45
50
55
60
y1. (sim)
y1
 
 
model9%29.8214
(e) Participant # 32 (29.82%)
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(f) Participant # 33 (29.23%)
Figure 3.58: Estimated model output vs. actual output (FM sym), using an ARX
[4 4 1] structure per model 9 (unless otherwise mentioned) for the participants of
full study. Model fits are mentioned in parenthesis.
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(a) Participant # 34 (48.72%)
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(b) Participant # 35 (18.08%)
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(d) Participant # 38 (54.69%)
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(e) Participant # 39 (40%)
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(f) Participant # 40 (59.34%)
Figure 3.59: Estimated model output vs. actual output (FM sym), using an ARX
[4 4 1] structure per model 9 (unless otherwise mentioned) for the participants of
full study. Model fits are mentioned in parenthesis.
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(a) Participant # 42 (54.13%)
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(b) Participant # 43 (22.95%)
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(c) Participant # 44 (27.98%)
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(d) Participant # 45 (27.84%)
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(e) Participant # 46 (31.17%)
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(f) Participant # 47 (40.31%)
Figure 3.60: Estimated model output vs. actual output (FM sym), using an ARX
[4 4 1] structure per model 9 (unless otherwise mentioned) for the participants of
full study. Model fits are mentioned in parenthesis.
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(a) Participant # 48 (66.41%)
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(b) Participant # 49 (33.19%)
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(c) Participant # 50 (58.99%)
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Figure 3.61: Estimated model output vs. actual output (FM sym), using an ARX
[4 4 1] structure per model 9 (unless otherwise mentioned) for the participants of
full study. Model fits are mentioned in parenthesis.
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Legend
• The system responses are grouped into four cases: DFM or Drug FM response, DS
or Drug overall sleep response, PFM or Placebo FM response and PS or Placebo
overall sleep response
• Kp (DFM/DS) is the gain (units of change in outcome per unit dose of LDN) and
Ts(.) is the settling time (in days) of system response.
• ESR (Erythrocyte Sedimentation Rate) values for each participant
• Two protocols have been followed: PD (Placebo followed by Drug) and DP (Drug
followed by Placebo)
• Goodness of fit of estimated models is shown by % fit
• “Average values” are the mean of data in respective columns
• * : Model using {Drug, Placebo, Anxiety, Stress, Mood, Life, Sadness and Gastric}
and λ using {Drug, Placebo, Anxiety, Stress, Mood, Life and Headache} as inputs
• μ : Model 7 formed using {Drug, Placebo, Anxiety, Stress, Mood, Gastric and
Headache}
• β : Model 9 using ARX [221] structure
• The standard deviation (σ ) on data is shown by ±. Please note that σ values in
rows corresponding to each participant is the variability on estimated gains (from
system identification) where as σ values in rows corresponding to average values is
the deviation of mean of each participant’s response.
• In some case due to large amount of missing data, a conclusive model was not formed
and this is represented by −.
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Figure 3.62: Original data time series (dashed) with three day moving averaged
data (solid) of FM sym variable for participants 3 through 9.
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Figure 3.63: Original data time series (dashed) with three day moving averaged
data (solid) of FM sym variable for participants 10 through 17.
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Figure 3.64: Original data time series (dashed) with three day moving averaged
data (solid) of FM sym variable for participants 18 through 27.
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Figure 3.65: Original data time series (dashed) with three day moving averaged
data (solid) of FM sym variable for participants 28 through 34.
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Figure 3.66: Original data time series (dashed) with three day moving averaged
data (solid) of FM sym variable for participants 35 through 42.
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Figure 3.67: Original data time series (dashed) with three day moving averaged
data (solid) of FM sym variable for participants 43 through 48.
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Figure 3.68: Original data time series (dashed) with three day moving averaged
data (solid) of FM sym variable for participants 49 through 54.
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3.6 Summary
The full study featured a longer protocol as compared to the pilot study. In addition,
the full study featured a double blind study as compared to single blind in the pilot
study. Looking at the response, we observe that the full study is inconclusive to the
question of whether the drug is effective or not. In a controlled experiment, it is
important to not only recognize any significant effect of a drug but that effect has to
be significant than the used experimental control (which is placebo in this clinical
trial). It is observed, based on this analysis, that many participants, particularly
from the full study, did not show conclusive response when comparing response
from drug with response from placebo.
We can also infer that the cases in which model fit or quality is very poor is
primarily because hardly any change is seen in the reported pain symptoms (See
Figures 3.62-3.68) and not necessarily due to shortcomings in the parametric iden-
tification. In other words, it means that there is little dynamics in the data to be
modeled; such trends indicate that the intervention did not have any significant ef-
fect on pain reports, for example. In comparison, the cases where relatively strong
response was observed (as in participant 5), the model was able to capture some of
those dynamics.
In summary, most of the pilot study participants were adequately modeled with
model 5 using the ARX [2 2 1] structure (unless otherwise noted) and in the full
study with model 9 using the ARX [4 4 1] structure (unless otherwise noted). Some
of the following conclusions are in agreement with the results obtained from data
analysis from both the pilot and full study:
• For some participants, models obtained from using only drug and placebo as
inputs had good fit and high magnitude gain. This implies that the primary
163
inputs (drug and placebo) have major impact on the outputs (FM symptoms
and overall sleep),
• As additional inputs are added in the model, the goodness of fit was observed
to improve. Five inputs (consisting of {Drug, Placebo, Anxiety, Stress and
Mood}) were shared in both the pilot and full studies.
• Adding typical output variables such as sleep and fatigue as inputs results in
overparametrization of the estimated model. In model structures 10 to 14,
more inputs such as sleep, fatigue and toleration of medicine are included.
Adding sleep as an input generally resulted in no significant improvement
in the goodness of fit for most of the participants. Adding toleration and
side effects in many cases caused marked changes in the model estimates,
among them unstable models. During the pilot study analysis we felt that
these additional variables reflected outputs more than inputs, and while their
inclusion in the model may increase the goodness-of-fit, in the absence of
crossvalidation data this does not necessarily imply that a better predictive
model has been obtained. Distinguishing between input and output variables
is important in this study, particularly in how it relates to overfitting models
and the absence of predictive ability in the estimated models.
The following two points have been a major shift for full study from the results
obtained in pilot study:
• The pilot data analysis was done with an ARX model of lower order ([2 2 1])
than the full study ([4 4 1]). Also the standard deviation bounds on estimated
gain from the pilot study are much closer as compared to the bounds obtained
from the full study. As a result, the distinction between responders and non-
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responders can become vague for borderline cases, and more so for the full
study.
• A major change over the pilot study is the response to placebo as input. We
have observed that a large group of participants can be classified as respon-
ders to placebo based on the gain of the placebo-FM model response includ-
ing many participant which had responded to the drug; this was consistent
across both protocols (PD and DP). It was also noted that based on classifi-
cation on average values, nonresponders (i.e., to drug) are (generally) nonre-
sponders to placebo as well.
In conclusion, we observe that not many participants show large change in pain
reports on the introduction of drug and in general, it was inconclusive as to whether
the drug naltrexone was, in many cases, stronger or effective than placebo. Despite
this general conclusion on this naltrexone intervention, the proposed methodology
provides a more detailed characterization of the response, and forms the basis for
adapting the intervention using control engineering approaches as described in the
next chapter.
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Chapter 4
CONTROL DESIGN FOR AUTOMATED DOSAGE ASSIGNMENTS
4.1 Overview
This chapter explores the problem of drug dosage assignment using techniques from
control system engineering. In this work, we implement an adaptive intervention
using the estimated models from system identification and a model predictive con-
trol (MPC) framework. The aim of the control design is two fold: a) to calculate
a control move so as to assign a (discrete-level) drug dosage for nominal control
performance, i.e. setpoint tracking with measured and unmeasured disturbance re-
jection; b) to implement a control formulation which is robust enough to handle
model uncertainties due to plant-model mismatch. The control results are shown
for case of a representative participant (‘participant 5’) to demonstrate the nominal
and robust performance using a three-degree-of-freedom (3 DoF) formulation of
MPC as described by Nandola and Rivera [31, 61] and Wang and Rivera [62]. The
control system aims at functionally performing the following three tasks:
• Setpoint tracking. Drug dosages are assigned to take an outcome of interest
(such as FM symptoms or overall sleep quality) to a desired goal. For exam-
ple, clinician may decide on a goal or setpoint of 45% reduction in general
pain symptoms within two weeks of drug administration.
• Measured disturbance rejection. The controller manipulates drug dosages
to mitigate the effect from reported external influences (e.g., anxiety) using
estimated disturbance models. For instance, if some external event which can
lead to stress is known a priori, then dosages can be adjusted to compensate
that disturbance.
• Unmeasured disturbance rejection. The controller manipulates drug dosages
to mitigate the effect of unknown and un-modeled external influences. For ex-
ample, any sudden event which leads to increased anxiety and thus worsening
pain condition. In such cases, the controller adjusts dosages for mitigate the
disturbance.
As was noted in Chapter 3, the plants are estimated using ARX [2 2 1] or ARX
[441] model structure and simplified to a second order continuous model with zero
(mostly LHP zeros). The system under consideration, for participant 5, is a 5 input-
1 output dynamical model with one manipulated variable (drug), four disturbance
variables (placebo, anxiety, stress and mood) and one output (FM symptoms). The
nominal performance of this control scheme is shown using different scenarios of
setpoint tracking. For the robustness case, we consider different parametric uncer-
tainties on the estimated models to generate scenarios for plant-model mismatch.
We showcase robustness as a proof-of-concept since a formal robustness treatment
for used hybrid MPC is beyond the scope of this thesis. The rest of the chapter is
organized as following. Section 4.2 deals with hybrid dynamics and Mixed Logical
Dynamical (MLD) representation. In Section 4.3 we introduce the model predic-
tive controller and tuning for MPC using the three-degree-of-freedom formulation.
In Sections 4.4 and 4.5, we discuss the aspects of nominal and robust performance
respectively. We conclude with summary in Section 4.6.
4.2 Hybrid Dynamical Systems
Hybrid dynamical systems can be considered to be a superset for classes of dynam-
ical systems. They can be identified by interacting continuous and discrete events
and their behavior can be described by the differential (or difference) equation de-
scribing their physical process and logic describing their binary or categorical be-
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havior. The binary constraints can be a part of the state, output or input as shown
below in three simple cases:
1. A piecewise linear dynamical system is when the state equation update de-
pends on a binary variable e.g.,
x(k+1) =
⎧⎪⎪⎨
⎪⎪⎩
A1x(k)+B1u(k) if δ = 0
A2x(k)+B2u(k) if δ = 1
(4.1)
y(k) =Cx(k)+Du(k) (4.2)
2. Output Nonlinearity is the case where the output from a linear system may
be under conditions like saturations, for example. In other words, y can take
only certain values which can be then described in terms of boolean logic.
An example is shown below (for simplicity, D = 0)
x(k+1) = Ax(k)+Bu(k) (4.3)
y(k) =
⎧⎪⎪⎨
⎪⎪⎩
C1x(k)≥ 1 if δ = 0
C2x(k)≤−1 if δ = 1
(4.4)
3. Discrete Inputs is the case where the input u may be required to take only
specific values in its domain under given circumstances e.g.,
x(k+1) = Ax(k)+Bu(k) (4.5)
u(k) =
⎧⎪⎪⎨
⎪⎪⎩
u1 if δ = 0
u2 if δ = 1
(4.6)
where δ is a discrete variable. It can be noted that since the inputs are produced
by the controller, the controller formulation should account for discrete inputs (in
168
contrast, the output discreteness may be due to the system dynamics). In this work,
the system exhibits hybrid characteristics due to the presence of categorical decision
making where drug dosage (or inputs) can only be assigned to discrete levels. All
states and output of the system are continuous i.e. none involve discrete/categorical
events. More detailed examples and explanations on hybrid dynamical systems can
be noted in [63, 64].
4.2.1 State Space Representation
In this work, we consider the following discrete time state space system
x(k+1) = Ax(k)+B1u(k)+Bdd(k) (4.7)
y(k+1) =Cx(k+1)+d′(k+1)+ν(k+1) (4.8)
where x and u represent states and inputs (e.g., drug) of the system. y represents
the output (e.g., FM sym) and d, d ′ and ν represent measured disturbances (e.g.,
anxiety), unmeasured disturbances and measurement noise signals, respectively.
It can be noted that the effect of measured disturbance has been assumed on the
state equation and the effect of unmeasured disturbance has been assumed on the
measurement equation. The reason for measured disturbance in the state equation
can be understood from the system dynamics. Consider a system with ns states and
ms inputs then in that case the resulting ‘B’ matrix is ns ×ms where some variables
will correspond to the manipulated input and will determine B1 and some variables
will be disturbance (measured) and will determine Bd . We use a nomenclature
of B1 so that we can incorporate other B matrices due to hybrid dynamics. The
unmeasured disturbance, in reality, can be affect both state and the output although
it is common to lump the effect in the measurement equation. One of the primary
reason for this is that the MPC formulation requires future predictions of outputs
(not states) and hence it is sufficient that this is modeled as described.
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Also consider a stochastic disturbance model
xw(k+1) = Awxw(k)+Bww(k)
d′(k+1) =Cwxw(k+1) (4.9)
where w is an integrated white noise and xw is the state of the noise term. This
model is motivated from process control where disturbances may be non-stationary
and hence this offers a general representation for a large class of scenarios. In this
work, Bw,Cw = I and Aw = 0. It can also be argued that the unmeasured disturbance
term can be modeled from estimated noise model from system identification e.g.,
d′ = H(q)e(t) where H(q) is the noise model and e(t) is white noise sequence (as
is Δw(k)). In addition to stochastic disturbances, unmeasured disturbances can also
be deterministic in character.
4.2.2 Mixed Logical Dynamical (MLD) systems
The most common hybrid system representations are piece wise affine (PWA) sys-
tems [65], mixed logical dynamical (MLD) systems [64] and linear complementary
(LC) systems [63]. These forms can be proved to be equivalent to each other under
certain assumptions [66]. The specific choice of hybrid system representation in
many ways depends on the intended use. In this work, the models are used for pre-
dictive control techniques. It can be noted that predictive control like MPC requires
explicit prediction of the system output (which will also be a function of discrete
or binary events). Hence we use the MLD type representation for hybrid systems
as it effectively combines the continuous and discrete dynamics. The key idea is
to convert boolean logic into linear inequalities involving integer and real variables
[67].
Extending on the general state space representation as shown in 4.7-4.8, the
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MLD systems model can be written as
x(k+1) = Ax(k)+B1u(k)+B2δ (k)+B3z(k)
+Bdd(k) (4.10)
y(k+1) =Cx(k+1)+d′(k+1)+ν(k) (4.11)
E2δ (k)+E3z(k)≤ E5 +E4y(k)+E1u(k)−Edd(k) (4.12)
where, in general, x = [xTc xTd ]T , xc ∈ Rn
c
x , xd ∈ {0,1}ndx and u = [uTc uTd ]T , uc ∈
R
ncu , ud ∈ {0,1}ndu , nu 	= ncu + ndu represent states (both discrete and continuous)
and inputs (both discrete and continuous) of the system. y ∈ Rny is a vector of
outputs, and d, d ′ and ν represent measured disturbances, unmeasured disturbances
and measurement noise signals, respectively as mentioned earlier. δ ∈ {0,1}nd and
z∈Rnz are discrete and continuous auxiliary variables that are introduced in order to
convert logical/discrete decisions into their equivalent linear inequality constraints.
Discussion on stability of MLD systems can be noted in [64].
The logical constraints used can be explained using an example. For illustration,
let the drug dosages be u(k) ∈ {0,4.5,9,13.5} mg i.e. drug can take only stipulated
four values. These discrete inputs (4 levels) that be represented logically as:
δ1(k) = 1 ⇔ z1(k) = 13.5;δ2(k) = 1 ⇔ z2(k) = 9 (4.13)
δ3(k) = 1 ⇔ z3(k) = 4.5;δ4(k) = 1 ⇔ z4(k) = 0 (4.14)
4
∑
i=1
δi(k) = 1 (4.15)
u(k) =
4
∑
i=1
zi(k) (4.16)
It can be noted that on using the two summation conditions, we make sure that only
one input level is selected. In this example each ‘state’ of the input was assigned
using a discrete variable. As an alternative, we can define these four levels using
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only two discrete variables and boolean logic. Also in a similar way, more categor-
ical levels (z) can be defined using less discrete variables (δ ) by the use of boolean
logic.
4.2.3 Prediction
MPC uses a p step ahead prediction (called as prediction horizon) which can be
called as open loop response to the calculated input u(t). This can be obtained
by starting from initial condition at t = k and propagating through the state and
measurement equations (and using the linear inequalities) to obtain the output y(k+
1). The process is repeated for remaining p−1 steps and hence finally y(k+1) to
y(k+ p) is obtained. The prediction vectors can be represented as:
Y (k+1) =
⎡
⎢⎢⎢⎢⎣
yT (k+1)
.
.
.
yT (k+ p)
⎤
⎥⎥⎥⎥⎦U (k) =
⎡
⎢⎢⎢⎢⎣
uT (k)
.
.
.
uT (k+m−1)
⎤
⎥⎥⎥⎥⎦
¯δ (k) =
⎡
⎢⎢⎢⎢⎣
δT (k)
.
.
.
δT (k+ p−1)
⎤
⎥⎥⎥⎥⎦
(4.17)
Z (k) =
⎡
⎢⎢⎢⎢⎣
zT (k)
.
.
.
zT (k+ p−1)
⎤
⎥⎥⎥⎥⎦D(k) =
⎡
⎢⎢⎢⎢⎣
d f lt T (k)
.
.
.
d f ltT (k+ p−1)
⎤
⎥⎥⎥⎥⎦
(4.18)
where Y (k+ 1), U , ¯δ , Z and D are future values of outputs, inputs, auxiliary
binary variables, auxiliary continuous variables and filtered measured disturbances.
The vector U , ¯δ , Z are calculated from the MPC problem where as the D is
available beforehand. It can be noted that D is a function of filtered disturbance
d f lt that is the filtered value of the measured disturbance obtained using a discrete
time filter and will be discussed in Section 4.3.2.
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Equations 4.10-4.12 can be used to obtain the prediction vector. But before
we proceed with prediction, the MLD system is augmented with the disturbance
model, as shown in Equation 4.9 and this will be used for prediction instead. It is
written in difference form ([68] for more information) as follows
X(k) =A X(k−1)+B1Δu(k−1)+B2Δδ (k−1)+B3Δz(k−1)
+BdΔd(k−1)+BwΔw(k−1) (4.19)
y(k) = CX(k)+ν(k) (4.20)
where,
X(k) = [ΔxT (k) ΔxTw(k) yT (k)]T
A =
⎡
⎢⎢⎢⎢⎣
A 0 0
0 Aw 0
CA Aw I
⎤
⎥⎥⎥⎥⎦ ; Bi =
⎡
⎢⎢⎢⎢⎣
Bi
0
CBi
⎤
⎥⎥⎥⎥⎦ , i = 1,2,3,d; Bw =
⎡
⎢⎢⎢⎢⎣
0
I
I
⎤
⎥⎥⎥⎥⎦ ;
C = [0 0 I]
and hence use Equations 4.19-4.20 to write the prediction equation which calculates
the vector Y (k+1) as:
Y (k+1) = ΦX(k)+H1U (k)+H2 ¯δ (k)+H3Z (k)+HdD(k)−H11u(k−1)
−H21δ (k−1)−H31z(k−1)−Hd1d f lt(k−1) (4.21)
E5 ≥ E2 ¯δ (k)+E3Z (k)+E1U (k)+E4X(k)+EdD(k)−E41u(k−1)
−E42δ (k−1)−E43z(k−1)−E4dd f lt(k−1) (4.22)
where Φ, H∗, H∗, E∗ and ¯E∗ are the appropriate coefficients matrices that can be
generated using (4.12), (4.19) and (4.20) as shown:
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Φ =
⎡
⎢⎢⎢⎢⎢⎢⎢⎣
CA
CA 2
.
.
.
CA p
⎤
⎥⎥⎥⎥⎥⎥⎥⎦
(4.23)
Hi1 =
⎡
⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
CBi
CABi
CA 2Bi
.
.
.
CA p−1Bi
⎤
⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
i = 1, 2, 3, d (4.24)
¯Ei = diag{Ei, · · · ,Ei}, i = 2, 3, d (4.25)
¯E4 = diag{−E4, · · · ,−E4} (4.26)
¯E5 = [E5 E5 · · · E5]T (4.27)
¯E1 =
⎡
⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
−E1 0 · 0
0 . . . · ...
.
.
. · · · · −E1
.
.
.
.
.
.
.
.
.
.
.
.
0 · · · · −E1
⎤
⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(4.28)
Ei = ( ¯E4 ¯Hi + ¯Ei), i = 1, 2, 3, d (4.29)
E4 = ¯E4 ¯Φ (4.30)
E4i = ¯E4 ¯Hi1, i = 1, 2, 3, d (4.31)
E5 = ¯E5 (4.32)
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¯H j =
⎡
⎢⎣ [0]ny
H j(1 : (p−1)ny, :)
⎤
⎥⎦
j = 1, 2, 3, d, 11, 21, 31, d1 (4.35)
¯Φ =
⎡
⎢⎣ C
Φ(1 : (p−1)ny, :)
⎤
⎥⎦ (4.36)
Here ny is number of outputs,[0]ny denotes matrix with ny rows that has all the
elements 0 and ∗(1 : (p−1)ny, :) is matrix’s (∗) row 1 to row (p−1)ny with all the
columns.
4.3 Model Predictive Control
MPC solves a finite horizon optimal control problem using the model prediction
to obtain the control move over a finite horizon (under given constraints). After
this, only the first value of control is applied and the same procedure is repeated
for the next sampling instant. MPC can be contrasted with other optimal control
approaches [69, 70, 71]. Traditionally, these use an infinite prediction horizon of
an unconstrained system where the control law can be precomputed. In contrast
in MPC, a finite horizon optimal control problem (possibly, a constrained problem
i.e. the admissible states and controls are bounded) is solved where the control is
calculated on-line at each sampling instant. Calculating the control move at each
instant and applying only the first calculated move makes sure that the controller is
more responsive to disturbances and hence this receding horizon strategy provides
closed loop robustness to the system.
In general, the prediction horizon is smaller than the control horizon. When
the disturbances are ‘measured’, they are part of the prediction and hence MPC
can effectively implement the feedback-feedforward control. As an example for
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Figure 4.1: Receding Horizon Control Strategy. The control moves are calculated
over control horizon of length m and only the first calculated move is implemented.
This process is repeated at each sampling instant.
the control strategy, we show a representative diagram explaining the process in
Figure 4.1. The first subplot represents the evolution of the system output as per
the prediction over p steps. The second subplot represents the plot of a measured
disturbance which will be a part of the prediction equation. Finally, in the third
subplot we show a calculated control move such that the goal is reached in m steps.
Some of the salient features of MPC are:
• Naturally suited for multi input multi output (MIMO) systems with con-
straints
• Effectively combines the feedback-feedforward control action
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• Applies a receding horizon strategy which can be summarized as
1. Calculating a system prediction.
2. Solving an optimization problem over a horizon.
3. Applying only the control move corresponding to current sampling time.
4. Going to the next sampling instant and repeating the process.
It is to be noted that the control moves are calculated such that after m steps,
there is no more control action or Δu(i) = 0 for i ≥ m.
4.3.1 Hybrid MPC’s Control Move
Under constraints (by limits on the domain for signals as well as by the hybrid
dynamics), we cannot write a state feedback control law directly as u = Kx where
K is the gain matrix. A standard quadratic cost function, through the l2-norm, is
used to calculate the decision vector as described below
min
{[u(k+i)]m−1i=0 , [δ (k+i)]p−1i=0 , [z(k+i)]p−1i=0 }
J 	=
p
∑
i=1
‖(y(k+ i)− yr)‖2Qy +
m−1
∑
i=0
‖(Δu(k+ i))‖2QΔu
+
m−1
∑
i=0
‖(u(k+ i)−ur)‖2Qu +
p−1
∑
i=0
‖(δ (k+ i)−δr)‖2Qd +
p−1
∑
i=0
‖(z(k+ i)− zr)‖2Qz
(4.37)
such that
ymin ≤ y(k+ i) ≤ ymax, 1 ≤ i ≤ p (4.38)
umin ≤ u(k+ i) ≤ umax, 0 ≤ i ≤ m−1 (4.39)
Δumin ≤ Δu(k+ i) ≤ Δumax, 0 ≤ i ≤ m−1 (4.40)
and also subjected to state, output and mixed integer constraints as shown in Equa-
tions 4.10-4.12 where p is the prediction horizon and m is the control horizon. The
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vector 2-norm are weighted by matrix Q∗ as in Qy, QΔu, Qu, Qd, and Qz are the
penalty weights on the error, move size, control signal, auxiliary binary variables
and auxiliary continuous variables, respectively. It is to be noted that the problem
is formulated as a tracking control system (as contrasted with a state regulator) us-
ing references yr,ur,δr and zr for output, input, discrete and continuous auxiliary
variables, respectively.
Using the vector prediction based on the state space model as shown in Equa-
tions 4.21-4.22, we can transform the objective function based on summation to
the one based on matrices and vectors. This new objective function can be formu-
lated as a inequality constrained mixed integer quadratic program (MIQP) as shown
below
minξ J
	
=
1
2
ξ TH ξ +G T ξ (4.41)
S ξ ≤ b (4.42)
where ξ = [U (k)T ¯δ (k)T Z (k)T ]T is the vector of the decision variables. More
details of the formulation with respect to the Hessian and gradient matrices can
be found in [31, 61]. It should be noted that since the sampling time is equal to
one day, the computation time for solving MIQP is a non-issue in this application.
Further discussion on optimal control of MLD systems, including computational
complexity, can be found in [64].
4.3.2 Tuning for MPC
Setpoint tracking using the nominal model in presence and absence of measured and
unmeasured disturbance can be used to define the nominal performance of the con-
troller. For this, the conventional MPC tuning rules rely on changing either p (the
prediction horizon), m (the control horizon) or penalty weights such as QΔu (move
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Figure 4.2: Three-degree-of-freedom (3 DoF) controller formulation of model pre-
dictive control.
suppression) which may not be very intuitive. We rely on a three-degree-of-freedom
(3 DoF) approach to tune our controller which enables performance requirements
associated with setpoint tracking, anticipated measured disturbance rejection and
unmeasured disturbance rejection to be adjusted independently ([61, 68]) by vary-
ing parameters αr, αd and fa respectively. These parameters can be adjusted be-
tween values 0 and 1; they in turn alter the response of Type I or Type II filters
which supply filtered signals to the controller (for setpoint tracking and measured
disturbance rejection) or adjust the observer gain (for unmeasured disturbance re-
jection). Hence, the controller can be detuned (as controller without filter will be
the case where it achieves best possible effect) as per the requirement of the prob-
lem. In the Figure 4.2, we show a 3 DoF controller formulation of model predictive
control in an extension of the classical control loop (Figure 1.2) where P,Pd are the
system plants, X(k/k), fa is the observer block,Y is the predictor block, minJ is the
optimizer block and f (q,α) are the filters for reference and measured disturbance
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signals.
• Setpoint tracking and measured disturbance rejection.
In this work, the setpoint tracking corresponds to the feedback action and
measured disturbance rejection to the feedforward action. Using a filter, we
can detune a controller to vary the closed loop response. Based on the system
at hand, we can filter using a Type I filter as shown below
f (q,α j) = (1−α
j)q
q−α j , 1 ≤ j ≤ ny (4.43)
or a Type II filters as shown in Equation 4.44-4.46
f (q,α j) = (β0 +β1q−1 + · · ·+βωq−ω)× (1−α
j)q
q−α j (4.44)
βk = −6kα
j
(1−α j)ω(ω +1)(2ω +1) , 1 ≤ k ≤ ω;1 ≤ j ≤ ny (4.45)
β0 = 1− (β1 + · · ·+βω) (4.46)
where ny is the number of outputs. In both cases, α can be varied to alter
the response. As noted earlier, the tuning parameter to alter the reference
trajectory response is denoted by αr and the tuning parameter for measured
disturbance filtering by αd . The set point or disturbances changes should be
asymptotically step or ramp and the choice of the filter depends on the type
of the system (integrating, for example) [62, 72]. In this work, we use Type
I filter for both cases where both αr,d ∈ [0,1). Hence the controller can be
tuned for slower rejection of measured disturbances, for example, by more
extensive filtering of the disturbance signals.
• State Estimation
A parametrized observer is used to handle unmeasured disturbances as dis-
cussed in [31, 68]. These disturbances can be applied externally and/or can
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originate from the plant-model mismatch. In this formulation, it is necessary
to separate the effect of measured and unmeasured disturbance of the state
estimation. Reference tracking is not a part of the prediction equation and
hence, by definition, is independent of both αd and fa. To truly separate this
effect, we track the measured disturbance and filtered measured disturbance
separately. Consider that both measured and unmeasured disturbances are
acting on the system and the filtering for respective signals is also initiated.
In first step, we obtain state estimation by considering actual measured dis-
turbance (d) using the Kalman filter-based approach as follows,
X(k|k−1) =A X(k−1|k−1)+B1Δu(k−1)+B2Δδ (k−1)
+B3Δz(k−1)+BdΔd(k−1) (4.47)
X(k|k) = X(k|k−1)+Kf (y(k)−CX(k|k−1)) (4.48)
where X is the augmented state of the system. This is the state of the system,
estimated under unmeasured disturbance only. In the second step, we obtain
state estimation using the filtered measured disturbance as shown
Xf lt(k|k−1) =A Xf lt(k−1|k−1)+B1Δu(k−1)+B2Δδ (k−1)
+B3Δz(k−1)+BdΔd f lt(k−1) (4.49)
Xf lt(k|k) = Xf lt(k|k−1)+Kf (y(k)−CX(k|k−1)) (4.50)
where Xf lt is the estimate corresponding to the effect of filtered measured
disturbance and unmeasured disturbance. Next, X f lt is used in the controller
formulation so that it can respond to changes in αd and fa. In this it was
assumed that there is no plant-model mismatch but even in presence of such
mismatch, the net effect will be an unmeasured disturbance.
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An optimal value of the filter gain K f can be found by solving an algebraic
Riccati equation which requires estimating the covariance matrices for the
unmeasured disturbance. In this work, no such a priori information is avail-
able. Therefore, following [68], we apply the parametrization of the filter
gain shown in general as:
Kf =
⎡
⎢⎢⎢⎢⎣
0
Fb
Fa
⎤
⎥⎥⎥⎥⎦ (4.51)
where
Fa = diag{( fa)1, · · · ,( fa)ny} (4.52)
Fb = diag{( fb)1, · · · ,( fb)ny} (4.53)
( fb) j = ( fa) j
2
1+α j −α j( fa) j , 1 ≤ j ≤ ny (4.54)
( fa) j is a tuning parameter that lies between 0 and 1. As ( fa) j approaches
zero, the state estimator increasingly ignores the prediction error correction
and the state estimator tries to compensate for all prediction error as ( fa) j
approaches 1, and hence the controller becomes extremely aggressive. Since
we consider asymptotically step inputs, α j = 0. Hence, Kf results in:
Kf =
⎡
⎢⎢⎢⎢⎣
0
( fa)2
fa
⎤
⎥⎥⎥⎥⎦ (4.55)
It can be noted that the parametrization of the observer gain causes correction in the
output of the system and not on the state since the first term is zero.
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4.3.3 Control Performance
Since the objective of the control system is to produce a desired output y by ma-
nipulating the input u, we can define performance requirements. Such performance
conditions will be set by the user as per the requirement by using the tuning meth-
ods discussed earlier. In the following sections, we look at broadly two set of
results: a) Nominal Performance where the system performance is noted when
there is no model uncertainty. It is important to note that we do not strictly spec-
ify the performance requirements but rather demonstrate how a 3 DoF formulation
gives flexibility and hence can be tuned as per the clinical requirements; b) Robust
Performance where the model is perturbed (thus causing a plant-model mismatch)
and hence the controller has to perform under these uncertainties . Deriving strict
robustness bounds is challenging for hybrid, constrained control and hence we use
model perturbation to simulate uncertainties. Nominal and robust performance are
evaluated assuming that the system has nominal and robust stability.
Some of the parameters for simulation are kept constant through out (unless
otherwise mentioned) and they are as follows: the controller horizons are p = 25
and m = 15; objective function weights are Qy = 1, QΔu = Qu = Qd = Qz = 0, and
T = 1 day is the sampling time.
4.4 Nominal Performance
The results in this section are broken down into various scenarios. Each of them
will be discussed within each sub-headings.
4.4.1 Hybrid vs. Continuous MPC
Since the discrete nature of drug dosages introduce a hybrid constraint, we compare
and contrast the performance of the hybrid controller and its continuous controller
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(i.e. where u can take any value over its domain). The performance also aims at
showcasing a 3DoF result. For reference, we restate the continuous time approxi-
mation of estimated 5 input ARX [2 2 1] model as:
FMsym(s)
Drug(s)
= G1(s) =
−2.47(1.96s+1)
(1.57)2s2 +2(1.26)(1.57)s+1 (4.56)
FMsym(s)
Anxiety(s)
= G3(s) =
0.86(0.24s+1)
(1.57)2s2 +2(1.26)(1.57)s+1 (4.57)
The gain for the drug-FM model is shown in per milligram of dosage.
In this simulation, the setpoint tracking starts at t = 0, measured disturbance
acts at t = 25 and unmeasured disturbance at t = 45. The output variable starts with
a baseline value of 50 and a change of −9.5 is applied at t = 0 as shown by the ref-
erence. The results are shown for two sets of tuning parameters as a) (αr,αd, fa) =
(0,0,1), which is the fastest possible setting for the control system; b) (αr,αd, fa)=
(0.5,0.5,0.5) where we de-tune the controller . The hybrid control result is shown
using eight drug dosage levels as u(k)∈{0,1.92,3.85,5.76,7.68,9.6,11.58,13.5}mg.
As shown in Fig. 4.3, it can be seen that the 3 DoF formulation allows us to tune
the controller independently for setpoint tracking and disturbance rejection. For
setpoint tracking, αr can be adjusted to suit the expected response. Similarly, the
response to disturbances can be varied by αd and fa to suit the conditions at hand.
By increasing filtering action, the dosage assignments are more smoother (and as
per clinical requirements) as compared to the unfiltered case and the continuous
MPC. For measured disturbances, continuous MPC offers perfect compensation
through the use of feedforward action where as in the case of hybrid MPC, the
action is less effective due to constraints. At t = 45 an abrupt change in the pain
report occurs due to an unmeasured disturbance (this change is not a part of model
prediction). The controller reacts by increasing the drug dosage to compensate. It
should be noted that as a result of maximum dosage restriction, we do not see much
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Figure 4.3: Performance of hybrid MPC (eight levels) with tuning parameters
(αr,αd, fa) = (0,0,1) (top) and (αr,αd, fa) = (0.5,0.5,0.5) (bottom); both cases
are compared to their continuous MPC counterparts.
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difference on how hybrid and continuous MPC handle unmeasured disturbance in
this example.
In Figure 4.4, we show the same scenario with slight change in tuning for per-
formance (αr,αd, fa) = (0.4,0.4,0.4)) and with the number of discrete levels now
dropped to only four, u(k)∈ {0,4.5,9,13.5} mg. The reference is now set at −11.1
from baseline value of 50; this is done in order to avoid offsets with changed input
levels. Due to fewer drug levels, it can be seen that hybrid controller, in this four
level scenario, changes dosages in as a ‘step’ as that is the best possible solution.
This can be contrasted to the eight level scenario where due to more options with
drug levels, we observe a ‘smoother’ transition. Even under these limitations, we
can observe a comparable performance with the continuous MPC. In both the fig-
ures, we have chosen the tuning to represent a typical response where as per the
nominal performance requirements, the tuning can be adjusted.
The MPC where u(t) as a continuous variable and with no filtering represents
the best possible performance by the controller. Clinically, this can be the first
benchmark which can be used to get a sense of treatment regimen from the control
system. Next, depending on the clinical constraint of drug dosage levels, a new
treatment regimen has to be generated and can be contrasted with the continuous
case. In both the mentioned case, the drug dosing may be too aggressive for comfort
of a clinician and hence, in that scenario based upon the exact requirements (e.g.,
pain reduction by 30%) the hybrid controller can be de-tuned. In the next, Section
4.4.2, we come some of the possible scenarios of setpoint tracking.
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Figure 4.4: Performance of hybrid MPC (four levels) with tuning parameters
(αr,αd, fa) = (0,0,1) (top) and (αr,αd, fa) = (0.4,0.4,0.4) (bottom); both cases
are compared to their continuous MPC counterparts.
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4.4.2 Setpoint Tracking
In this section, we analyze how changing tuning parameters modifies performance.
In setpoint tracking, the controller keeps track of the goal (e.g., pain reduction)
by assigning drug dosages. Since we have three parameters to adjust (αr,αd, fa),
there are many possible permutations. For sake of brevity, we narrow it down to
following scenarios. In each of these cases, we keep αd and fa constant and then
different αr are tried:
• When there is no disturbance at t = 0 (Figure 4.5)
• When there is only an unmeasured disturbance acting at t = 0 of magnitude
4.72 (Figure 4.6)
• When there is only an measured disturbance (in anxiety report) acting at t = 0
of magnitude 11.05 (Figure 4.7)
• When there are both unmeasured and unmeasured disturbance (of magnitude
as above) acting at t = 0 (Figure 4.8)
For reference, we restate that keeping αr and αd near zero will result in the least
amount of filtering and vice-versa. For unmeasured disturbance rejection, moving
fa away from one will result in slower rejection. In the previous section, setpoint
tracking was disturbance free (as we split the time line to emphasize the 3DoF) but
in this section we run through cases where simultaneous disturbances and reference
tracking are present. In traditional MPC, move suppression is used to influence the
speed of reponse but in this work we use the 3DoF formulation which can produce
better results in a more intuitive way as the tuning parameters are directly related to
the speed of response. Another interpretation of these tuning results are that since
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they are shown in time domain, the user can choose the three tuning parameters as
per requirement more intuitively.
From the results shown in Figure 4.5 through Figure 4.8, we see that by ad-
justing αr, it is possible to adjust the speed of setpoint tracking. In general, αr in
vicinity of 0.5 works well for a smoother response. In presence of disturbances, the
setpoint tracking is also dependent upon disturbance rejection and then the suitable
choice of αr depends on disturbance tuning (αd, fa) as well. In Figure 4.5, there
are no disturbances present and decreasing the tuning results in increasing sluggish
response. Similar results are seen in Figure 4.6 under the presence of an unmea-
sured disturbance under two tunings ( fa = 1 and fa = 0.2). In case of fa = 1, we
see complete disturbance rejection which gives a tighter control. Figure 4.7 shows
tracking under measured disturbance from anxiety report with plot corresponding
to αd = 0.9 gives a more sluggish response. Finally, Figure 4.8 shows tracking
under both measured and unmeasured disturbances where a smoother (but more
aggressive) response is obtained for αd = 0 and fa = 1. In all of the cases men-
tioned before, the variation of αr from 0 to 0.8 (as seen on the Y-axis) results in
more sluggish setpoint tracking speed. It can also be observed in Figure 4.5-4.8
that to compensate the effect of disturbance, more dosage magnitude is required.
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Figure 4.5: Setpoint tracking under no disturbances for various tuning (αr) values.
Setpoint is denoted by dotted lines.
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Figure 4.6: Setpoint tracking under unmeasured disturbance for various tuning (αr)
values with two settings for fa. Setpoint is denoted by dotted lines.
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Figure 4.7: Setpoint tracking under measured disturbance for various tuning (αr)
values with two settings for αd . Setpoint is denoted by dotted lines.
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Figure 4.8: Setpoint tracking under both unmeasured and measured disturbance
for various tuning (αr) values with two settings for αd, fa. Setpoint is denoted by
dotted lines.
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4.4.3 Stochastic Unmeasured Disturbance
So far, a deterministic (step) unmeasured disturbance has been considered. The
controller performance can also be evaluated when the disturbance is white or is
colored (e.g., Autoregressive moving average (ARMA)). We show only the case
where the noise is colored to simulate a disturbance whose average value is chang-
ing over time. By changing the observer gain through fa, it is possible to influence
disturbance rejection.
The ARMA model which has a zero at 0.5 and a two poles at 0.9 can be repre-
sented as:
d(t) = (q−0.5)
(q−0.9)2 a(t) (4.58)
where d,a are discrete signals, q is the forward shift operator. The time series re-
alization as shown in Figure 4.9 using the MATLAB plot command. The original
noise a(t) is zero mean with variance 0.1. The two simulation cases are shown in
Figure 4.10 and are compared with respective continuous MPC. In the first case,
we apply fa = 1 where as in the second case, fa = 0.1 resulting in a sluggish re-
sponse (and hence a longer realization was shown (t = 175) to see the full cycle). A
measured disturbance of magnitude 11.05 acts at t = 25 (αr and αd = 0.5 for both
cases). Also, the drug dosage levels can take any of the designated eight levels.
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Figure 4.9: ARMA time series realization.
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Figure 4.10: Performance of hybrid MPC under different tuning ( fa = 1,0.1) when
the unmeasured disturbance is a realization of ARMA noise model.
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4.5 Robust Performance
We consider a 5 input 1 output model whose inputs are drug, placebo, anxiety, stress
and mood. Robust performance addresses the scenario where a perfect model is not
available from identification. Plant-model mismatch will result in some prediction
error which can be influenced by the observer through fa. Modeling errors in drug-
FM model will be compensated through the feedback action alone although for
modeling errors in anxiety-FM model, for example, will be partially compensated
by the feedforward action and what ever signal is not compensated by the anticipa-
tion, will enter the feedback loop as unmeasured disturbance. We assume that none
of the plant-mismatch scenarios result in plant instability.
We can formulate various scenarios for testing robustness using simulations.
For example, consider when the plant is nominal and the disturbance model is per-
turbed. It is also possible to perturb the plant model but keep it same or constant
for different disturbance model uncertainties. For simplicity, we perturb only the
drug-FM model (‘plant model’) and the anxiety-FM model (‘disturbance model’).
We go through different permutations of these cases of which three broad scenarios
are as following:
1. Only the plant model is perturbed
2. Only the disturbance model is perturbed
3. Both plant and disturbance models are perturbed
The results are shown in two major groups: first, a tuning parameter is fixed and
the effect of different uncertainties is observed as is shown in Section 4.5.1. Second,
the uncertainty is fixed and the effect of tuning ( fa) on the response if observed as
shown in Section 4.5.2. For each scenario, we evaluate different uncertainties in
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the plant and disturbance models. As mentioned earlier, the plant model is fixed as
drug-FM model and disturbance model as anxiety-FM model. It can be observed
that when no filtering is imposed, the result is more aggressive controls. Similarly
when some uncertainty is fixed, we can see better results from less filtering.
Before describing the results, it is important to mention how robust performance
results are grouped. In each simulation figure, we use the following two functional
groupings:
1. When a fixed nominal model is used. A nominal model is used as a basis for
the controller to assign dosages for different plants. This case can be under-
stood in two ways: first, in the classical interpretation where the estimated
model is an approximation of the true system and second, when the nomi-
nal model represents an average or representative model, with a single, fixed
controller assigning dosages to different participants within this population.
2. When the true plant serves as the nominal model. For each scenario consid-
ered in the previous case, we supply the true plant as the nominal model to the
controller. This case can be understood as when accurate modeling (through
system identification or otherwise) has been performed for each individual in
a population.
Each of these two groups will be demonstrated when examining model uncertainties
as shown in Figures 4.11-4.19; each case of model uncertainty is complemented
by the scenario where we have a ‘correct’ model of each uncertainty. The key
motivation for this is to get a clinical insight as the user can now compare how the
controls will vary under plant-model mismatch (typical robustness scenario) and on
the same page, it will help us asses the case when the correct model is available to
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the controller. Hence, the user can gauge the resultant change in dosing strategies
due to modeling errors.
The uncertainties used for plant model P are
1. Nominal model (no mismatch);
2. ΔKp = (−14.8%);
3. ΔKp = (14.8%);
4. ΔKp,Δζp,Δτp = (−14.8%,−16.6%,259%);
5. ΔKp,Δζp,Δτp = (14.8%,79.3%,−29.1%)
and for the disturbance model Pd, the uncertainities are
1. nominal model (no mismatch);
2. ΔKd = (−14.8%);
3. ΔKd = (14.8%);
4. ΔKd,Δζd,Δτd = (−14.8%,−16.6%,259%);
5. ΔKd,Δζd,Δτd = (14.8%,79.3%,191%)
The motivation for choosing these values is to start with gain perturbations and then
move to cases where both parameters of the characteristic equation are changed
along with the gain. The gain change direction is in both positive and negative
direction.
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4.5.1 Robustness Evaluated under Fixed Tuning
In this subsection, the controller tuning is fixed and then different uncertainties
are evaluated. It is to be noted that αr = 0 and αd = 0 and hence we only vary
fa. The setpoint is kept constant at 0 and a measured disturbance is applied at
t = 5 of magnitude 11.05. The plant-model mismatch will contribute to unmeasured
disturbance so it is not applied externally in the simulation.
In Figures 4.11-4.16 each scenario (‘Y’ axis) represents one of the five cases of
uncertainty as mentioned above. We show the three cases (plant model only per-
turbed, disturbance model only perturbed and both plant and disturbance models
perturbed) in six figures, two for each cases. It can be seen that as fa moves from
fa = 0.2 to fa = 1 we get tighter control but it may result in overshooting. All
the cases are compared with respective scenarios where a correct nominal model
is available and it can be observed that the control is better as expected. In Fig-
ures 4.11 and 4.12, only plant model is perturbed. In Figures 4.13 and 4.14, only
disturbance model is perturbed. Finally, in Figures 4.15 and 4.16 both plant and
disturbance models are perturbed. With addition of more uncertainty as shown in
Figures 4.11-4.16 requires higher dosage of drug for corresponding compensation.
It is also to be noted that scenario 1 in all plots is the case of nominal model where
there is no steady state error.
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Figure 4.11: Robustness evaluation when only plant model (drug-FM) is perturbed
under tuning fa = 0.2.
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(b) Closed loop response where true plant serves as the nominal model (no plant
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Figure 4.12: Robustness evaluation when only plant model (drug-FM) is perturbed
under tuning fa = 1.
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(b) Closed loop response where true plant serves as the nominal model (no plant
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Figure 4.13: Robustness evaluation when only disturbance model (anxiety-FM) is
perturbed under tuning fa = 0.2.
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Figure 4.14: Robustness evaluation when only disturbance model (anxiety-FM) is
perturbed under tuning fa = 1.
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(b) Closed loop response where true plant serves as the nominal model (no plant
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Figure 4.15: Robustness evaluation when both disturbance model (anxiety-FM) and
plant model (drug-FM) are perturbed under tuning fa = 0.2.
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Figure 4.16: Robustness evaluation when both disturbance model (anxiety-FM) and
plant model (drug-FM) are perturbed under tuning fa = 1.
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4.5.2 Robustness Evaluated under Fixed Uncertainty
In this subsection, the tuning of the controller is varied with a fixed uncertainties
in the plant model, disturbance model combination. Each scenario on the ‘Y axis’
represents a case for fa: scenario 1 is for fa = 0.2 and scenario 5 is for fa = 1.
Hence, as we move away from fa = 1 along the axis, we see less and less distur-
bance rejection.
In Figures 4.17-4.19 we show how the tuning affects the performance more
precisely than previous section as we now fix the uncertainty. In each case, fa =
1 results in more aggressive control. As earlier, each control is compared with
the case where a correct nominal model is available where the control is better
as expected. If the user has some sense for the expected modeling uncertainties,
we can see different control inputs under different tunings. A clinician can then
choose certain tuning parameters which can then prescribe best possible treatment
regimens.
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Figure 4.17: Robustness evaluation under different fa (with αr = αd = 0) when
only plant model (drug-FM) is perturbed using plant uncertainty case number 4 as
ΔKp,Δζp,Δτp = (−14.8%,−16.6%,259%).
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(b) Closed loop response where true plant serves as the nominal model (no plant
model mismatch)
Figure 4.18: Robustness evaluation under different fa (with αr = αd = 0) when
only disturbance model (anxiety-FM) is perturbed using disturbance uncertainty
case number 4 as ΔKd,Δζd ,Δτd = (−14.8%,−16.6%,259%).
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(b) Closed loop response where true plant serves as the nominal model (no plant
model mismatch)
Figure 4.19: Robustness evaluation under different fa when both plant model (drug-
FM) and disturbance model (anxiety-FM) are perturbed using plant uncertainty case
number 4 as ΔKp,Δζp,Δτp = (−14.8%,−16.6%,259%) and using disturbance un-
certainty case number 3 as ΔKd = (14.8%).
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4.6 Summary
The aim of this chapter is to demonstrate how a control system framework can be
used in an adaptive intervention for fibromyalgia. We use a representative partici-
pant from the clinical trial and using estimated models from system identification,
we show how a model predictive controller can be used to assign dosages in pres-
ence of disturbances and model uncertainties. The control results are shown using
simulation and are broadly classified under nominal performance and robust perfor-
mance. Under nominal performance it is shown how by varying the three param-
eters (αr,αd, fa), we can achieve independent tuning for setpoint tracking (taking
pain report to a goal), measured and unmeasured disturbance rejection. We also
demonstrate how different settings of these parameters will lead to different time
responses and demonstrate the usefulness for both deterministic and stochastic dis-
turbances.
In the robust performance evaluation, we perturb the model parameters to create
conditions of a plant-model mismatch which is then used by the controller. In this
scenario, we run two broad cases: one where controller tuning is fixed and the effect
of different uncertainties are noted and second, when the plant uncertainty is fixed
and the effect of tuning is evaluated on the resulting response. Due to constraints
on the input drug dosage levels, the plant uncertainties were not chosen arbitrarily
very large and it can be noted that in such a scenario, an unconstrained MPC can
achieve much higher mismatches where as constrained control will saturate.
In all the responses pertaining to the nominal and robust performance of the
controller as noted in many of the Figures 4.5-4.19, we observe that the hybrid con-
troller tries its best to track the goal under given constraints and that may result in an
oscillatory input drug assignment. This treatment regimen would be the best pos-
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sible result under given models and clinical constraints. Hence, it is demonstrated
that even under considerable uncertainty and since the modeling effort is always
lacking, an acceptable performance is achieved.
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Chapter 5
CONCLUSIONS
5.1 Summary
In this thesis, we have demonstrated how techniques from system identification and
hybrid model predictive control (HMPC) can be used to evaluate and design an
adaptive intervention. We showcase the case of drug dosage levels assignment of
naltrexone for the treatment of fibromyalgia as a proof of concept. The work in this
thesis can be broadly divided into two areas: dynamical modeling and control.
We performed a secondary data analysis of data obtained from a clinical study
to estimate parsimonious dynamical system models. The modeling procedure was
split into three parts: first part deals with the preprocessing of the data for removing
high frequency content as well as handling issues of missing data. In the primary
second step, we fit the estimation data to parametric ARX model of order [2 2 1]
or higher. The model is then validated using standard residual analysis as well a
sense of model uncertainty is obtained through the model error model approach
and using bounds on the step response of estimated models. During this process of
parametric modeling, we systematically look at the two sources of errors in system
identification: bias error and variance errors. We also note that the experimental
data can be considered to be generated in a closed loop experiment (and as observed
by correlated variables) and hence a prediction-error framework works as a good
initial choice. After working through the data for all 40 participants, we observed
that ARX [221] or ARX [441] proved to be sufficient without resulting in a case of
over parametrization. These multi-input models best described the output variance
among give choice of inputs. The inputs were selected such that they have minimum
cross correlation and will result in minimum bias errors. Since the intervention aims
at testing the efficacy of the drug (low dose naltrexone), drug is always included as
the primary input. Also since the experimental design for this clinical trails used
a placebo as an experimental control, placebo is also included as input. Working
further from these two inputs, we found that many other variables reported in the
daily diary data such as anxiety, stress, mood can be potentially added as input
helping improve the fit of the dynamical models. Most of the participants of the
pilot study conformed to a model structure which used drug, placebo, anxiety, stress
and mood as inputs and most of the participants in the full study conformed to a
model which adds gastric, headache, life and sadness to variables in the pilot data
study.
In the final step of our system identification procedure, we approximate the esti-
mated discrete time parametric model with a second order continuous models with
a zero. We found that this structure was adequate to represent the observed dynam-
ics. This model is then used to extract useful information about the effect of drug
on pain symptoms, for example, through gain of the model and other parameters
affecting the time response. These parameters are represented in the step response
tabulation for multi input models. Based on the nominal gain of the drug-FM sym
model, we can classify participants as responders (the model gain Kp will be neg-
ative) or in other words whose pain reports go down with drug intervention and as
non-responders (the model gain Kp will be positive) whose pain reports stay the
same or go up with drug intervention. Since in clinical trails, the aim is to separate
the drug response from the placebo response, we note the gain of placebo-FM sym
model and which has to be, ideally, positive (implying increase in pain) or in lesser
magnitude than the drug response. Based on these criteria, we classify a large group
of participants as responders (total 26, see Tables 3.8-3.9 and Tables 3.21-3.24) al-
though many of these cases lie on the borderline. Similar classification of gain can
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be made in the case when ‘overall sleep’ is used as the output where a positive gain
would imply improvement in sleep quality with drug intervention and hence the
participant is a responder in that sense. Chapter 2 and 3 cover the modeling aspect
of this work.
As a conclusion to dynamic modeling, we revisit questions raised in Chapter 2,
Section 2.7 regarding the effectiveness of this clinical intervention.
• Does a participant respond to the drug?
The participants are classified as responders and responders based on models
from system identification. Very few participants showed a strong response
to drug (e.g., participant 5) while in most of the cases, the response ranged
from mild to no response.
• If yes, then how fast does the drug cause a measurable effect?
We observed a large variability in settling time values from model step re-
sponses. On an average over pilot and full study, we can say that the drug
took over 2−3 weeks to show full effect.
• How does the response compare for different outcomes?
In the pilot study, the response of FM sym and overall sleep variables to drug
for responders are similar which means that those who had relief from pain
generally enjoyed better sleep qualities. In the case of responders in the full
study, this relationship was not observed. In case of non-responders from
both studies, some showed improvement in sleep.
• How does the participant respond to placebo?
Ideally, for responders to drug it is expected that the response to placebo is
increase in pain. This was not observed for all responders; many of the par-
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ticipants in both pilot and full studies who had been classified as responders
based on the drug-FM model were also ‘responders’ to placebo. The placebo
response was stronger in the full study as compared with the pilot study.
• How can the response of two different participants be compared?
It is difficult to compare the response quantitatively between participants be-
cause the data is obtained through self-reports though we can qualitatively
compare that one participant shows as stronger response to drug than the
other for example, participant 5 has a stronger response than participant 40
(both responders).
The dynamical model describing the effect of drug, placebo, anxiety, stress and
mood on FM sym can now be used by the controller. In a typical clinical set-
ting, the physician may use patient characteristics (e.g., vital signs, pathological
information) to make a dosage change; in case of naltrexone intervention the self-
reports completed by the participants can be used as patient characteristics (which
can be better described by the dynamical model). Additionally, successful handling
of disturbances or external influences is critical from a standpoint of an effective
treatment plan. It is likely obvious to the reader that the traditional method is not
systematic, and is neither robust nor optimal. In this approach of using control
systems, greater efficacy can be obtained. To assign drug dosages, a hybrid model
predictive control approach, as shown in [31, 61, 73], has been utilized which can
allow independent tuning for disturbance free setpoint tracking, measured distur-
bance rejection and unmeasured disturbance rejection. The physician may set a
certain goal both in terms of magnitude of response expected and the time frame
of the treatment (setpoint tracking). The controller will prescribe a dosage regi-
ment based on those requirements. Since the MPC control law is updated on every
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sampling instant based on the ‘feedback’ from self-reports, the control law will be
updated in case of a disturbance (measured and unmeasured disturbance rejection).
These requirements can be grouped under nominal performance of the controller
and through simulations, we show how this hybrid control framework can be used
tune the system response as specified by the clinical requirements.
Since any modeling effort will not result in an exact description of the real
system, the controller formulation should be robust enough to handle plant-model
mismatch and unknown disturbances. From simulation results, we show that this
MPC setup maintains the outcome variable at goal in presence of disturbance and
uncertainties. A physician can get a sense of the drug dosage regiment prescribed
by the controller in case of modeling errors and hence can get information on how
aggressive or sluggish the regiment may become due to mentioned mismatches.
The Chapter 4 covers the discussion on control for naltrexone intervention. The
approach described in this work generates models from experimental data and con-
siders hybrid dynamics in an MLD framework. It offers a broad-based methodology
that can be applied in an similar application setting involving adaptive interventions.
5.2 Future Work
Many goals of adaptive interventions, personalized medicine and control engineer-
ing converge to a common factor emphasizing the extraction of the maximum pos-
sible potential of the underlying system while using minimum resources. Modeling
of biological phenomena as dynamical systems will not only result in greater under-
standing of the process but will allow systematic use by the controller to optimize
the process. The future research thrust will be towards methods for modeling and
control of systems to be used in an adaptive intervention.
An area of future work is the design of experimental protocols. As the informa-
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tion content of the used input signal for system excitation is crucial for the success
of system identification, design of protocols for plant-friendly and informative data
set is required. Clinical trials are primarily designed with a fixed dosage strategy (a
binary input) and hence the data set may not necessarily very informative. Further,
a input signal exceeding two (binary) levels is required for finding nonlinearities.
In addition, the experimental design has to be as per given clinical constraints e.g.,
the drug levels should not change abruptly from lowest dosage to highest dosages.
An experimental design can be suggested which would involve a deterministic pe-
riodic signal dosage, e.g., multilevel pseudo random sequence as shown in Figure
5.1, designed such that it has persistence of excitation in the bandwidth of interest
based on some a priori information.
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Figure 5.1: A Multilevel pseudo random sequence altering between drug dosages
of 0.5−2.5−4.5 mg with a 14 day baseline and washout period.
Further computational approaches for local modeling are required to work with
finite date set and hence as a part of nonlinear identification, approaches such as
Model-on-Demand (MoD) [74, 75] can be utilized on the collected informative
data set from these new protocols. These new databases can also be organized for
multiple participants to generate models for large cohorts. Apart from modeling
issues related to input signal quality and parametric identification, there is also a
need to better understand the underlying feedback mechanism of complex biologi-
cal systems from experimental data.
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The presented formulation of hybrid model predictive controller can be modi-
fied such that it is more suited for adaptive interventions by further integration of
treatment related constraints. First, since MPC only requires explicit output/state
predictions near operating conditions, the local models from MoD utilizing the in-
formative dataset can be used for more precise future predictions. Next, it is more
practical to allow setpoint bands for tracking as compared to a strict setpoint value
where a clinician can choose a band of pain level for example; this will also lead
to less aggressive dosing. Finally, ideas from robust control can be used for the
uncertainty set obtained from system identification procedures. In conclusion, the
motivation is to improve existing tools for effective system identification and con-
trol as well as to develop new methods which can guarantee robust performance
under given clinical constraints.
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